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3Introduction
The Primary Care Reimbursement Service (PCRS) is 
responsible for reimbursing GPs, Dentists, Pharmacists, 
Optometrists/Ophthalmologists and other contractors 
who provide free or reduced-cost services to the public 
across a range of community health schemes. These 
schemes form the infrastructure through which the HSE 
delivers a significant proportion of primary care to the 
public. In total, 3.6 million people were registered for 
primary care schemes in 2018.  
This year the statistical report of claims and payments 
is much reduced as many of the tables that appeared in 
previous reports have now been made available online.  
Visit www.hsepcrs.ie and choose “PCRS Publications” to 
access the full range of reports which are updated on a 
monthly basis.
The online Medical Card application offering to the 
public (www.medicalcard.ie) has proved hugely 
beneficial and since November 2018, applications for 
the Drugs Payment Scheme card can also be made 
online (www.mydps.ie). The online submission of claims 
by practitioners and the electronic ordering of High 
Tech drugs are further steps towards automating our 
processes.
Altogether, in 2018 PCRS made total payments and 
reimbursements of €2.9 billion to approximately 
7,000 contractors under the GMS, Drugs Payment, 
Dental Treatment, Long Term Illness and Community 
Ophthalmic Schemes and in relation to High Tech and 
other arrangements. 
 
As at 31st Dec 2018, 2,068,378 or 43.4% of the 
population had medical card or GP visit card eligibility.  
Free GP care for Carers in receipt of Carer’s Allowance 
or Carer’s Benefit was introduced on 1st Sept 2018 and 
over 3,000 Carers were newly registered by the end of 
the year.
On behalf of the HSE, I would like to thank all of 
our clients and contractors for their co-operation 
throughout 2018 and I look forward to working with you 
to continue to improve all of the services we provide 
into the future. 
I would also like to take this opportunity to thank 
the staff in the Primary Care Reimbursement Service 
involved in the continued delivery of day to day services, 
for their contribution and commitment to the delivery 
of these vital support services to the public.
Anne Marie Hoey
Assistant National Director 
Primary Care Reimbursement Service
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6Schemes – Claim Reimbursement and Payment Arrangements
During 2018, HSE Primary Care Reimbursement 
Service reimbursed claims and made payments to 
General Practitioners (GPs), Community Pharmacists, 
Dentists and Optometrists/Ophthalmologists totalling 
€2,908.29m, in respect of medical card and national 
primary care schemes.
Claim data is processed and reimbursements are made 
by the Primary Care Reimbursement Service under the 
following Schemes:
General Medical Services (GMS)
Persons who are unable without undue hardship to 
arrange general practitioner medical and surgical 
services for themselves and their dependants are 
eligible for the GMS Scheme. Drugs, medicines and 
appliances approved under the Scheme are provided 
through Community Pharmacists. In most cases 
the GP gives a completed prescription form to an 
eligible person, who takes it to any Pharmacy that 
has an agreement with the Health Service Executive 
to dispense drugs, medicines and appliances on 
presentation of GMS prescription forms. In rural areas a 
small number of GPs hold contracts to dispense drugs 
and medications to GMS cardholders who opt to have 
their medicines dispensed by him/her directly.
All GMS claims are processed and paid by the Primary 
Care Reimbursement Service. Since the 1st October 2010, 
an eligible person who is supplied a drug, medicine or 
medical or surgical appliance on the prescription of a 
Registered Medical Practitioner, Registered Dentist or 
Registered Nurse Prescriber, was charged a prescription 
charge by the Community Pharmacy.
From 1st March 2017, the prescription charge for 
persons aged 70 & over, and their dependents, was 
reduced from €2.50 to €2.00 per item and the monthly 
cap for prescription charges decreased from €25.00 to 
€20.00 for this cohort.
From 1st January 2018, the prescription charge for 
persons and their dependents was reduced from €2.50 
to €2.00 per item and the monthly cap for prescription 
charges decreased from €25.00 to €20.00. 
The prescription charge is recouped by the HSE from the 
Pharmacist. 
General Practitioner Visit Card (GPVC)
The GP Visit Card was introduced for people in Ireland 
who are not eligible for a GMS medical card, to obtain 
GP services free of charge. GP Visit Cards are provided to 
eligible individuals and families who meet the qualifying 
criteria. All applications for GP Visit Cards and associated 
GP claims are processed and reimbursed by the Primary 
Care Reimbursement Service. From 1st July 2015, all 
children under 6 years of age were eligible to obtain GP 
services free of charge. From 5th August 2015, all persons 
over 70 years of age were eligible to obtain GP services 
free of charge.
Medical cards for children with Domiciliary Care 
Allowance (DCA) eligibility
The Health (Amendment) Act 2017 provides for the 
granting of full medical card eligibility to children in 
respect of whom a Domiciliary Care Allowance (DCA) is 
payable. The Minister for Health announced that, with 
effect from 1st June 2017, such children aged under 
16 years who do not already have full eligibility will be 
eligible to receive a medical card. 
Medical cards for children with cancer
From 1st July 2015, following a recommendation of the 
Clinical Advisory Group, the HSE extended medical card 
eligibility to all children under the age of 18 years with a 
diagnosis of cancer.
GP Visit Card for persons in receipt of Carer’s 
Allowance or Carer’s Benefit
The Health (General Practitioner Service) Act 2018 
provides for the granting of eligibility for GP services 
without charge to all those in receipt of full, or half-rate, 
Carer’s Allowance or Carer’s Benefit. From 1st September 
2018, all persons in receipt of Carer’s Allowance or 
Carer’s Benefit were eligible to obtain GP services free of 
charge.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments and 
clinical procedures comprised of Routine Treatments 
and Full Upper and Lower Dentures. Routine Treatments 
are available for all eligible persons. Dentists may 
also prescribe a range of medicines, as part of their 
treatment, to eligible persons. 
HSE Community Ophthalmic Services Scheme (HSE-
COSS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card holders 
and their dependants are entitled, free of charge, to 
eye examinations and necessary spectacles/appliances. 
Claims by Optometrists/Ophthalmologists are paid by 
the Primary Care Reimbursement Service. Claims for 
spectacles provided under the Children’s Scheme are 
also paid by the Primary Care Reimbursement Service.
7Drugs Payment Scheme (DPS)
The Drugs Payment Scheme (DPS) provides for payment 
to the Pharmacist for the supply of medicines to 
individuals and families where the threshold of €134, 
effective from 1st January 2018, has been exceeded in a 
calendar month. In order to avail of the Drugs Payment 
Scheme a person or family must register for the Scheme 
with the HSE PCRS. Drugs, medicines and appliances 
currently reimbursable under the Scheme are listed on 
the HSE website. Other items which were reimbursable 
under the Drug Cost Subsidisation Scheme and Refund 
of Drugs Scheme continue, in certain circumstances, to 
be reimbursable under the Drugs Payment Scheme. 
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive, persons 
who suffer from one or more of a schedule of illnesses 
are entitled to obtain, without charge, irrespective of 
income, necessary drugs/medicines and/or appliances 
under the LTI Scheme.
European Economic Area (EEA)
Residents from one of the other states of the European 
Economic Area, with established eligibility, who require 
emergency general practitioner services while on a 
temporary visit to the State are entitled to receive 
from a General Practitioner a GMS prescription form 
for necessary medication and to have such medication 
dispensed in a Pharmacy that has entered into an 
agreement with the Health Service Executive within the 
State. 
High Tech Arrangements (HT)
Arrangements are in place for the supply and 
dispensing of High Tech medicines through Community 
Pharmacists. Such medicines are generally only 
prescribed or initiated in hospital and would include 
items such as anti-rejection drugs for transplant patients 
or medicines used in conjunction with chemotherapy 
or hormonal therapy. The medicines are purchased 
by the Health Service Executive and supplied through 
Community Pharmacists for which Pharmacists are paid 
a patient care fee. The cost of the medicines and patient 
care fees are paid by the Primary Care Reimbursement 
Service.
High Tech Hub Ordering and Management System
In December 2017 PCRS introduced a new High Tech 
medicines ordering and management hub. This is 
an online system in which Hospital Consultants and 
prescribers can register patients for High Tech medicines 
and can prepare and print prescriptions for those 
patients. Pharmacists can view and order High Tech 
medicines from suppliers and manufacturers through 
the High Tech hub.
In turn, suppliers can accept and arrange for the delivery 
of ordered medicines to Community Pharmacists.  
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation Scheme 
provides for immunisation of the total child population 
with the aim of eliminating, as far as possible, such 
conditions as Diphtheria, Polio, Measles, Mumps, 
Rubella and more recently Meningococcal C Meningitis. 
Payments to GPs under this Scheme are made by the 
Primary Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain health 
services are made available without charge to persons 
who have contracted Hepatitis C directly or indirectly 
from the use of Human Immunoglobulin - Anti D or the 
receipt within the State of another blood product or 
blood transfusion. GP services, pharmaceutical services, 
dental services and optometric/ophthalmic services 
provided under the Act are paid for by the Primary Care 
Reimbursement Service.
Opioid Substitution Treatment Scheme
Methadone and Medicinal Products containing 
Buprenorphine are prescribed by Doctors and dispensed 
by Pharmacists for approved clients under the Opioid 
Substitution Treatment Scheme - capitation fees payable 
to participating GPs and Community Pharmacists 
and claims by Pharmacists for the ingredient cost of 
the Methadone and Medicinal Products containing 
Buprenorphine dispensed and the associated 
dispensing fees are processed and paid by the Primary 
Care Reimbursement Service.
Immunisations for GMS Eligible Persons
Agreement was reached between the Department of 
Health and the Irish Medical Organisation on fee rates 
to be applied to certain immunisations for GMS eligible 
persons. The immunisations encompassed by the 
agreement are - Pneumococcal, Influenza, Hepatitis B 
and the combined Pneumococcal /Influenza.
Schemes – Claim Reimbursement and Payment Arrangements  continued
8Discretionary Hardship Arrangements
Medical Card patients, for whom Non GMS reimbursable 
items have been prescribed, may make application to 
the HSE Community Healthcare Organisation (CHO) for 
approval to have such items dispensed by a Community 
Pharmacist. Previously, the CHO reimbursed Community 
Pharmacists directly in respect of such prescribed items. 
In July 2009 reimbursement for these items transferred 
to the Primary Care Reimbursement Service. 
Centralised reimbursement of selected high cost 
drugs administered or dispensed to patients in 
hospitals
The HSE commenced the centralised reimbursement of 
selected Oncology and Hepatitis C drugs. 
The National Cancer Control Programme (NCCP) 
established the National Cancer Drug Management 
Programme to develop and improve the care provided 
to patients receiving treatment with oncology drugs.  
A national management system for cancer drugs 
was set up within the PCRS to facilitate centralised 
reimbursement and data capture of selected high-cost 
oncology drugs. This allows national oversight of the 
expenditure on high-cost oncology drugs in line with 
approved indications, improved service planning and 
budgetary projections and a national approach to 
provision of oncology drugs. 
The Hepatitis C drugs are dispensed to patients in the 
designated adult hepatology units.
Centralised reimbursement of Outpatient Parenteral 
Antimicrobial Therapy (OPAT)
The HSE commenced the centralised reimbursement 
of Outpatient Parenteral Antimicrobial Therapy (OPAT) 
drugs, medicines and appliances administered by 
healthcare professionals or self-administered by patients 
in the community.
Redress for Women Resident in Certain Institutions 
Under the Redress for Women Resident in Certain 
Institutions Act 2015, it was provided that the Health 
Service Executive (HSE) would make available specified 
services to women eligible for the Restorative Justice 
Scheme, administered by the Department of Justice and 
Equality. Services include General Practitioner services, 
drugs, medicines and medical and surgical appliances, 
dental, ophthalmic and aural services, home nursing 
service, home support service, chiropody services, 
physiotherapy services, and a counselling service. Card 
holders are not required to pay any prescription fees.
Schemes – Claim Reimbursement and Payment Arrangements  continued
9Summary Statement of Activity - 2018
l  Payments and reimbursements during 2018 were 
approximately €2,908.29m.
l  Claim data is processed and reimbursements 
are made by the HSE PCRS under the following 
Schemes:
 n General Medical Services (GMS);
 n Drugs Payment Scheme (DPS); 
 n Long Term Illness (LTI);
 n Dental Treatment Services Scheme (DTSS);
 n European Economic Area (EEA);
 n High Tech Arrangements (HT);
 n Primary Childhood Immunisation;
 n Health (Amendment) Act 1996;
 n Opioid Substitution Treatment Scheme; 
 n  Health Service Executive Community 
Ophthalmic Services Scheme (HSE-COSS).
l  Total fees and allowances of €565.41m were paid to 
GPs.
l  Over 77m prescription items were paid for by the 
PCRS – an increase of over 1.78m items on 2017. 
l  A total of €93.55m was paid in prescription charges 
in 2018.
l Total fees of €375.20m were paid to Pharmacists.
l Payments to Pharmacists totalled €1,317.63m:
 n  GMS: Prescriptions €960.19m, Stock Order 
Forms €6.16m; 
 n DPS €67.36m;      
 n LTI €242.69m;
 n EEA €0.82m;
 n  The Health (Amendment) Act 1996, Opioid 
Substitution Treatment Scheme, DTSS 
prescriptions, and Pharmacy Training Grants 
€16.18m;
 n  Patient Care Fees of €23.36m were paid to 
pharmacists under High Tech Arrangements;
 n Influenza Vaccination Scheme €0.87m.
 n  Payments to Manufacturers/Wholesalers 
of High Tech drugs and medicines totalled 
€781.23m.
l  Payments to Dentists under the DTSS totalled 
€58.68m.
l  Payments to Optometrists/Ophthalmologists 
under the HSE-COSS totalled €29.83m.
l  Centralised reimbursement of certain approved 
high cost Oncology, Hepatitis C drugs and 
medicines and Outpatient Parenteral Antimicrobial 
Therapy (OPAT) drugs, medicines and appliances 
totalled €116.03m. 
l Administration costs were €38.99m.
Note: The figures detailed above have been rounded for 
reporting purposes.
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Total Payments & Reimbursements 2018 - €2,908.29m
GP Fees  €411.75m
GP Allowances €153.66m
Investment in General Practice Development €0.49m
Pharmacist Drugs and Medicines €919.07m
Pharmacist Fees and Stock Order Mark-Up €375.20m
Pharmacist High Tech Patient Care Fees €23.36m
Manufacturers / Wholesalers High Tech Drugs and Medicines €781.23m
Dentists €58.68m
Optometrists / Ophthalmologists €29.83m
Hospital - Oncology Drugs and Medicines €44.95m
Hospital - Hepatitis C Drugs and Medicines €64.62m
Outpatient Parenteral Antimicrobial Therapy (OPAT) - Drugs, Medicines and Appliances €6.46m
Administration €38.99m
Total Payments and Reimbursements – 2018
The figures detailed above have been rounded for reporting purposes.
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The figures detailed above have been rounded for reporting purposes.
l  Fees paid to GPs include €8.17m in respect of the 
Primary Childhood Immunisation Scheme, €0.19m 
in respect of the Health (Amendment) Act 1996 
and €7.97m in respect of the Opioid Substitution 
Treatment Scheme. 
l  Payments to Pharmacists include €1.42m in respect 
of drugs/medicines dispensed under the Health 
(Amendment) Act 1996, €13.45m in respect of the 
Opioid Substitution Treatment Scheme, €0.47m 
in respect of Pharmacy Training Grants, €0.84m 
in respect of DTSS prescriptions and €0.87m in 
respect of the Influenza Vaccination Scheme. 
l  Fees paid to Pharmacists include €75.70m in 
respect of the phased dispensing of a reimbursable 
item based on one of the reasons specified under 
the agreement between the Department of Health 
and Children and the Irish Pharmaceutical Union. 
l  Payments to Optometrists/Ophthalmologists 
include €2.26m in respect of Optical Services for 
Children, €0.46m in respect of Optical Services for 
Teenagers and €0.12m in respect of treatments 
under the Health (Amendment) Act 1996. 
l The corresponding figures for 2017 are:
 n  Total payments and reimbursements 
€2,748.70m.
 n  GP Fees €398.91m and GP Allowances 
€152.66m.
 n Phased Fees €84.43m.
 n  Investment in General Practice Development 
€0.57m.
 n  Pharmacy Drugs and Medicines €915.24m, 
Fees and Stock Order Mark-Up €376.96m.
 n  Payments to Dentists under the DTSS 
€63.37m.
 n  Payments to Optometrists/Ophthalmologists 
under the COSS €32.71m.
 n  High Tech Arrangements – Payment to 
wholesalers €664.22m which includes a 
deduction related to returned stock and 
patient care fees paid to pharmacists of 
€20.95m.
 n Hospital Oncology Drugs €29.00m.  
 n Hospital Hepatitis C Drugs €53.78m.
 n  Outpatient Parenteral Antimicrobial Therapy 
(OPAT) €6.40m. 
 n Administration costs were €33.93m.
Total Payments and Reimbursements – 2018  continued
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General Practitioners  2,921 Pharmacists 1,870 Dentists 1,644 Optometrists 608
The number of agreements between the Health Service Executive and General Practitioners for the provision of services to GMS 
cardholders reflects the policy position agreed between the Department of Health and the Irish Medical Organisation on entry to the GMS 
Scheme. At December 2018 there were 2,921 agreements.
Number of Agreements as at 31st December 2018
Community Healthcare Organisation General Practitioners Pharmacists Dentists Optometrists 
CHO Area 1 233 169 155 64
CHO Area 2 316 198 182 74
CHO Area 3 246 156 108 48
CHO Area 4 473 273 337 75
CHO Area 5 289 210 185 65
CHO Area 6 281 160 102 54
CHO Area 7 374 241 227 86
CHO Area 8 337 246 162 79
CHO Area 9 372 217 186 63
National 2,921 1,870 1,644 608
Number of Agreements with Contractor Groups
Note: Included in the table above are the following:
 (i)   430 GPs not contracted to the GMS Scheme who are registered to provide services under the Primary Childhood Immunisation Scheme, the 
Health (Amendment) Act 1996, Heartwatch, Opioid Substitution Treatment Scheme and National Cancer Screening Service.
 (ii)  11 Pharmacists who are registered to provide services under non GMS Schemes.
 (iii)  158 Dentists employed by the HSE who provide services under the Dental Treatment Services Scheme.
 (iv)  28 Clinical Dental Technicians.
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Number of Agreements with Contractor Groups 2009 - 2018
Year General Practitioners Pharmacists Dentists Optometrists 
2009 2,663 1,630 1,570 555
2010 2,740 1,671 1,582 574
2011 2,758 1,690 1,639 573
2012 2,832 1,713 1,730 580
2013 2,888 1,744 1,790 582
2014 2,870 1,778 1,827 586
2015 2,889 1,801 1,847 587
2016 2,914 1,830 1,831 593
2017 2,928 1,849 1,604 595
2018 2,921 1,870 1,644 608
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Community Healthcare Organisation *GPs **Pharmacy ***DTSS HSE-COSS
CHO Area 1 €52,346,356 €116,533,009 €6,454,835 €2,846,375
CHO Area 2 €61,647,353 €135,308,205 €5,870,869 €2,943,272
CHO Area 3 €50,038,523 €111,813,121 €4,981,140 €2,366,591
CHO Area 4 €90,223,911 €194,571,964 €9,281,021 €3,720,985
CHO Area 5 €70,843,273 €160,701,880 €8,542,808 €3,927,729
CHO Area 6 €42,407,222 €82,294,749 €2,850,707 €1,673,728
CHO Area 7 €64,576,443 €164,501,498 €7,008,502 €3,505,114
CHO Area 8 €72,328,367 €164,649,684 €7,742,156 €3,598,170
CHO Area 9 €60,999,549 €146,850,046 €5,948,163 €2,405,087
National €565,410,997 €1,277,224,156 €58,680,201 €26,987,051
Corresponding figures for 2017 €551,575,350 €1,274,716,074 €63,369,808 €29,892,456
Total Payments to Contractor Groups by CHO 2018
Note:  (i)   *GP figures include GMS and non GMS GPs.
 (ii)  **Pharmacy figures include GMS, Stock, DPS, LTI and EEA claims.
 (iii)  ***Dental figures include HAA claims since 2017.
Pharmacy €1,277,224,156
GPs €565,410,997
DTSS €58,680,201
HSE-COSS €26,987,051
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High Tech Wholesaler and Manufacturer Payments 2018
Company Amount Paid
Uniphar Group (Dublin) €384,845,314
United Drug Wholesale  
 -  United Drug Wholesale (Dublin) €117,482,871
 -  United Drug Wholesale (Limerick) €58,423,447
 -  United Drug Wholesale (Ballina) €39,194,598
Pfizer Healthcare Ireland €75,323,538
Vertex Pharmaceuticals (Ireland) Limited €64,000,000
Astellas Pharma Ireland €18,185,058
HE Clissmann €4,844,423
PCO Manufacturing €4,361,281
Xentra Pharm Limited €4,316,620
Gilead Sciences, Inc €3,804,872
Novo Nordisk €2,123,768
GlaxoSmithKline (Ireland) Limited €1,348,236
Merit Pharmaceuticals €707,973
Incyte Biosciences €580,920
Imed €539,561
Raptor/ Horizon €348,771
Temperature Controlled Products €266,683
Eurodrug €200,447
AllPhar Services €151,197
Clonmel Healthcare Ltd €101,076
Galway Drug Company Ltd €83,710
Total for 2018 €781,234,364
Total for 2017 €664,215,525
Note:     The figures in the above table relate to payments made to Wholesalers and Manufacturers of High Tech Drugs and Medicines in 2018.
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High Tech Trends 2009 - 2018
The graph illustrates how the increase in the number of people dispensed to has impacted on the High Tech spend over a 10 year period 
2009 - 2018.
Year High Tech Spend No. of Items Dispensed *No. of Persons Dispensed to
2009 315,355,866 336,996 53,515
2010 345,758,331 340,138 54,974
2011 350,181,003 361,419 60,888
2012 385,035,723 443,981 59,276
2013 442,271,580 466,485 63,701
2014 484,706,257 491,678 66,264
2015 544,185,172 530,368 70,321
2016 611,737,633 573,867 74,877
2017 664,215,525 622,596 81,580
2018 781,234,364 684,582 84,109
* Based on data available from claims submitted by Pharmacists.
CARDHOLDER
SECTION
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Number of Eligible Persons per Scheme - 2018
GMS 1,565,049 GPVC 503,329 DPS 1,290,634 LTI 281,075
Figures as at 31st December 2018
Community Healthcare Organisation GMS GPVC *DPS *LTI
CHO Area 1 163,070 39,835 16,332 15,602
CHO Area 2 165,347 47,137 26,614 15,636
CHO Area 3 137,693 39,837 23,989 15,326
CHO Area 4 225,003 77,006 49,837 25,647
CHO Area 5 199,736 53,646 28,902 22,201
CHO Area 6 79,158 53,453 30,864 13,760
CHO Area 7 204,597 65,910 39,294 24,371
CHO Area 8 218,774 64,187 34,565 24,099
CHO Area 9 171,671 62,318 35,202 20,839
National 1,565,049 503,329 285,599 177,481
** % of Population 32.87% 10.57% 6.00% 3.73%
GMS - General Medical Services Scheme. GPVC - GP Visit Card Scheme. DPS - Drugs Payment Scheme. LTI - Long Term Illness Scheme.
*The DPS and LTI figures shown refer to the number of eligible patients for whom claims were submitted to PCRS by pharmacies.
**National population figures are based on the Census figures for 2016.
Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and ophthalmic 
services for themselves and their dependants are provided with such 
services under the GMS Scheme. Since 1st October 2010, a person who is 
supplied by a Community Pharmacy Contractor with a drug, medicine or 
surgical appliance on the prescription of a Registered Medical Practitioner, 
Registered Dentist or Registered Nurse Prescriber is charged a prescription 
charge, currently (1st January 2018) €2.00 per item subject to a limit of 
€20.00 per family per month and this charge is recouped from payment 
to the Pharmacist. An eligible Person is entitled to select a GP of his/her 
choice, from among those GPs who have entered into agreements with the 
Health Service Executive. Drugs, medicines and appliances prescribed by 
participating GPs for their GMS patients are provided through Community 
Pharmacies. Dental and ophthalmic services are provided by Dentists and 
Optometrists/Ophthalmologists who have contracted with the Health 
Services Executive. GMS prescription forms may be dispensed in any 
Pharmacy that has an agreement with the Health Service Executive to 
dispense GMS prescription forms. 
In rural areas, where a GP has a centre of practice three miles or more from 
the nearest Community Pharmacy participating in the Scheme, the GP 
dispenses for those persons served from the centre who opt to have their 
medicines dispensed by him/her. The number of eligible GMS persons at 
year end included 16,356 persons who were entitled and had opted to have 
their medicines dispensed by their GPs.  
Under the terms of the Drugs Payment Scheme, persons who do not have a 
medical card may apply for a Drugs Payment Scheme card on an individual 
or family unit basis. Prescribed medicines, which are reimbursable under 
the GMS Scheme, costing in excess of a specified amount per month, €134 
during 2018, per family, is claimed by the Pharmacy and is paid by the 
Primary Care Reimbursement Service.
On approval by the Health Service Executive, persons who suffer from one 
or more of a schedule of illnesses are entitled to obtain, without charge, 
irrespective of income, necessary drugs/medicines and/or appliances under 
the LTI Scheme. The Primary Care Reimbursement Service makes payments 
on behalf of the Health Service Executive for LTI claims submitted by 
Pharmacies.
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Number of Eligible Persons per Scheme 2009 - 2018
Figures as at 31st December
Year GMS GPVC *DPS *LTI
2009 1,478,560 98,325 663,127 127,636
2010 1,615,809 117,423 494,550 134,926
2011 1,694,063 125,657 429,102 59,274
2012 1,853,877 131,102 370,791 69,513
2013 1,849,380 125,426 308,357 71,926
2014 1,768,700 159,576 278,227 111,940
2015 1,734,853 431,306 269,930 138,415
2016 1,683,792 470,505 270,525 153,446
2017 1,609,820 487,510 265,891 166,818
2018 1,565,049 503,329 285,599 177,481
GMS - General Medical Services Scheme. GPVC - GP Visit Card Scheme. DPS - Drugs Payment Scheme. LTI - Long Term Illness Scheme.
*The DPS and LTI figures shown refer to the number of eligible patients for whom claims were submitted to PCRS by pharmacies.
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GMS: Summary of Statistical Information for 2014 - 2018
Year ended December:- 2018 2017 2016 2015 2014 Year ended December:- 2018 2017 2016 2015 2014
(i) Number of Eligible Persons in December 2,068,378 2,097,330 2,154,297 2,166,159 1,928,276 Number of GP Contracts 2,921 2,928 2,914 2,889 2,870
Number of Pharmacist Contracts 1,870 1,849 1,830 1,801 1,778
General Practitioners (000's) (000's) (000's) (000's) (000's) (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €531,631 €522,375 €515,166 €460,973 €424,646 Total Cost of Stock Orders € 6,165 € 6,529 € 6,553 € 7,168 € 7,731
         Ingredient Cost € 4,663 € 4,980 € 5,023 € 5,514 € 5,991
(ii) Avg. Payment to GPs per Eligible Person €257.03 €249.07 €252.12 €226.07 €235.06
         Pharmacy  Fees € 933 € 996 € 1,005 € 1,104 € 1,199
 
Pharmacists (000's) (000's) (000's) (000's) (000's)          VAT € 569 € 553 € 525 € 550 € 541
Total Cost of Prescriptions € 960,185 € 983,304 € 1,026,737 € 1,047,136 € 1,111,214 Overall Cost of Drugs and Medicines € 966,350 € 989,833 € 1,033,290 € 1,054,304 € 1,118,945
     
        Ingredient Cost € 621,634 € 635,268 € 673,260 € 695,478 € 756,825 (iii) Avg. Payment to Pharmacists per 
Eligible Person € 679.40 € 677.16 € 671.44 € 673.33 € 677.39
        Dispensing Fee € 309,306 € 314,685 € 318,580 € 316,374 € 317,861  
 *Overall Payments €1,497,981 €1,512,208 €1,548,456 €1,515,277 €1,543,591
        VAT € 29,245 € 33,351 € 34,897 € 35,284 € 36,528
Number of Forms 18,949 18,979 19,244 19,011 19,351
Number of Items 59,218 58,595 58,683 57,973 59,407
    
Avg. Cost per Form € 50.67 € 51.81 € 53.35 € 55.08 € 57.43
 
Avg. Cost per Item € 16.21 € 16.78 € 17.50 € 18.06 € 18.71
   
Avg. Ingredient Cost per Item € 10.50 € 10.84 € 11.47 € 12.00 € 12.74
 
Avg. Items per Form 3.13 3.09 3.05 3.05 3.07
Note: (i)  Number of eligible persons in 2018 includes the number of eligible persons with Medical Cards and GP Visit Cards.
 (ii)  Average payment to GPs is inclusive of GP Visit card costs and exclusive of superannuation paid to retired DMOs.
 (iii)  Average pharmacy payment per person is calculated on the number of persons who availed of services during 2018. The number of persons who availed of services in 2018 was 1,422,350.
 (iv)  Overall payment per eligible person is based on the number of persons who availed of services during 2018.
 (v)  *Overall Payments includes payments made under Discretionary Hardship Arrangements.
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LTI / DP Schemes: Summary of Statistical Information for 2014 - 2018
Year ended December:- 2018 2017 2016 2015 2014 Year ended December:- 2018 2017 2016 2015 2014 
LTI Scheme DP Scheme
     Number of Eligible Persons in December 1,290,634 1,258,531 1,272,771 1,301,952 1,332,816
 
*Number of Claimants 177,481 166,818 153,446 138,415 111,940 *Number of Claimants 285,599 265,891 270,525 269,930 278,227
  
(000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 8,936 8,305 7,594 6,759 4,697 Number of Items 7,633 7,135 7,204 7,159 7,007
   
Total Cost €242,694 €221,904 €207,445 €189,484 €139,191 Gross Cost €157,050 €148,335 €153,670 €155,869 €156,272
      
Avg. Cost per Item €27.16 €26.72 €27.32 €28.03 €29.64 **Net Cost €67,363 €62,095 €65,300 €67,109 €67,534
   
*Avg. Cost per Claimant €1,367.44 €1,330.21 €1,351.91 €1,368.95 €1,243.45 Avg. Gross Cost per Item €20.57 €20.79 €21.33 €21.77 €22.30
   
*Avg. Net Cost per Claimant €235.87 €233.53 €241.38 €248.61 €242.73
Note: (i)  *These figures are based on the number of eligible persons who availed of services under each Scheme.
 (ii)  ** The Net Cost is inclusive of claims below the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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Ages Male € Female €
Under 5 Years 74.59 72.76
5 - 15 43.29 43.79
16 - 44 55.26 90.37
45 - 64 110.38 121.29
65 - 69 116.28 129.72
The Capitation rate is €125 for GPs who hold a contract for children under 6.
The above rates are exclusive of Supplementary Out-of-Hours Fee of €3.64.
The Capitation rate is €271.62 per annum for persons aged 70 years and over in the community issued with a medical card.
A Capitation rate of €434.15 per annum will apply to anyone aged 70 years and over in a private nursing home 
(approved by the Health Service Executive) for a continuous period in excess of five weeks.
Out-of-Hours Payment
Surgery (6 p.m. - 8 a.m.) €41.63
Surgery (8 - 9 a.m. and 5 - 6 p.m.) €13.88
Domiciliary €41.63
Additional Fee (Surgery or Domiciliary) €13.88
Special Items of Service
A Excisions / Cryotherapy / Diathermy of Skin Lesions €24.80
AB Long Acting Reversible Contraceptive (LARC) €70.00
AC Removal Long Acting Reversible Contraceptive (LARC) €50.00
AD 24 Hour Ambulatory Blood Pressure Monitoring €60.00
AE Cervical Screening Consultation €50.00
B Suturing of cuts and lacerations €50.00
C Draining of Hydroceles €24.80
D Treatment and Plugging of Dental and Nasal Haemorrhages €24.80
F ECG Tests and their Interpretation €24.80
H Removal of adherent foreign bodies from the conjunctival surface of the eye €24.80
J Removal of lodged or impacted foreign bodies from the ear, nose and throat €24.80
K Nebuliser treatment in the case of acute asthma attack €37.21
L Bladder Catheterization €60.00
M Attendance at case conferences (where authorised by the HSE) €62.02
R Pneumococcal Vaccination €28.50
S Influenza Vaccination €15.00
T Pneumococcal / Influenza Vaccinations €42.75
U Hepatitis B Vaccination €142.57
V H1N1 Vaccination €10.00
Fees and Allowances under Capitation Agreement as at 31st December 2018
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Fees and Allowances under Capitation Agreement as at 31st December 2018  continued
Temporary Residents/EEA Visitors/Emergency
Surgery €40.94
Domiciliary €40.94
Fee for Second Medical Opinion €26.46
Rural Practice Allowance
Rural Practice Allowance Per Annum €16,216.07
Rural Practice Support Framework Allowance Per Annum, where there is one or no other practice unit in the area €20,000.00
Rural Practice Support Framework Allowance Per Annum, where there are two practice units in the area 
however, one or both practice units is not in receipt of Rural Practice Allowance €10,000.00
Opt-in GP (dispensing doctor) €38.03
Pilot GP (dispensing doctor) €43.88
Continuous GP (dispensing doctor) €12.48
Practice Support
Allowance for Practice Secretary up to a maximum Per Annum of: €24,068.99
Allowance for Practice Nurse up to a maximum Per Annum of: €37,822.72
Allowance for Practice Manager up to a maximum Per Annum of: €30,945.86
Contributions to Locum Expenses (Subject to the conditions of the Agreement)
Annual Leave Up to a maximum of €1,380.65 per week
Sick Leave Up to a maximum of €1,380.65 per week
Study Leave 
Up to a maximum of €197.24 per day
Adoptive Leave
Maternity Leave
Paternity Leave
Contributions to Medical Indemnity Insurance
Calculation of contributions related to GMS panel numbers and net premium
Asylum Seekers
A once off superannuable registration fee of €173.69 per patient is payable to GPs in respect of 
patients on their GMS panel who are seeking asylum in Ireland
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GP Surgery Consultations Special Items of Service
Day Normal Hours €11.87 AE Cervical Screening Consultation €50.00
Late Outside Normal Hours other than (Night) €16.88 F Suturing of cuts and lacerations €22.43
Night Midnight to 8:00 a.m. €33.38 G Treatment and Plugging of Dental and Nasal Haemorrhages €22.43
H Draining of Hydroceles €22.43
Domiciliary Consultations J Recognized Vein Treatment €22.43
Day €17.51 K Excisions / Cryotherapy / Diathermy of Skin Lesions €22.43
Late €22.93 M ECG Tests and their Interpretation €22.43
Night €44.96 N Instruction in the fitting of a diaphragm €22.43
R Pneumococcal Vaccination €28.50
Temporary Residents/EEA Visitors/Emergency S Influenza Vaccination €15.00
Surgery €40.94 T Pneumococcal / Influenza Vaccinations €42.75
Domiciliary €40.94 U Hepatitis B Vaccination €142.57
V H1N1 Vaccination €10.00
Rural Practice Allowance
Per Annum €7,042.91 Immunisation Fees
Registration of child with a GP €37.78
Locum and Practice Expense Allowance 6 in one Vaccine €206.31
Per Annum €1,371.06 95% uptake bonus €60.63
Sessional Rate - Homes for the Aged Health (Amendment) Act 1996
Per 3 Hour Session €73.18 Surgery Fee €30.53
Domiciliary Fee €40.27
Opioid Substitution Treatment Scheme
Level 1 Contractor €159.97
Level 2 Contractor €176.43
Heartwatch Programme
Heartwatch Programme €39.31
Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health (Amendment) Act 1996,
Opioid Substitution Treatment Scheme and Heartwatch Programme as at 31st December 2018
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Fees and Allowances under the Capitation / Fee-Per-Item Agreement as at 31st December 2018
Type 2 Diabetes - Cycle of Care 
A once off registration fee of €30.00 per registered patient.
Following registration, GPs receive the monthly element of the agreed annual fee of €100.
Children in the Community aged Under 6
The Capitation rate is €125.00 per annum for children aged under 6 years issued with a GP Visit card.
This rate includes the Supplementary Out-Of-Hours fee, effective 1st July 2015.
Children aged Under 6 - Asthma Cycle of Care
A once off registration fee of €50.00 for children aged under 6 years diagnosed with asthma.
Following registration, GPs receive the monthly element of the agreed fee of €90 in the first year and 
receive the monthly element of the agreed fee of €45 in subsequent years up to the child’s 6th birthday.
Special Items of Service - Under 6
A Excisions / Cryotherapy / Diathermy of Skin Lesions €24.80
D Treatment and Plugging of Dental and Nasal Haemorrhages €24.80
H Removal of adherent foreign bodies from the conjunctival surface of the eye €24.80
M Attendance at case conferences €62.02
W Nebuliser treatment in the case of acute asthma attack €37.21
X Removal of lodged or impacted foreign bodies from the ear, nose and throat and skin €24.80
Y Suturing of cuts and lacerations (including application of tissue glue) €37.21
Z Draining of Abscesses €24.80
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Payments to General Practitioners 2018
Payments to GPs in each CHO Area
Community Healthcare Organisation 2018
CHO Area 1 €52,346,356
CHO Area 2 €61,647,353
CHO Area 3 €50,038,523
CHO Area 4 €90,223,911
CHO Area 5 €70,843,273
CHO Area 6 €42,407,222
CHO Area 7 €64,576,443
CHO Area 8 €72,328,367
CHO Area 9 €60,999,549
National €565,410,997
Payments to GPs includes reimbursement of claims in respect of services provided to Medical Card and GP Visit Cardholders. Reimbursement of claims made by GPs
includes expenditure of  €8,165,994  under the Primary Childhood Immunisation Scheme; €190,053  under the Health (Amendment) Act 1996;
€924,060 for Heartwatch; €16,531,928 for the National Cancer Screening Service and €7,967,821 under the Opioid Substitution Treatment Scheme.
Fees €411.75m Allowances €153.66m
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principal fee is the capitation per person which is 
weighted for gender and age -  capitation fees totalled €277,190,633 
in 2018, an increase of €698,461 when compared to 2017. Fees 
totalling €447,013 were paid to 3 GPs who continue to provide 
services under the Fee-Per-Item of service agreements. 
Apart from ‘Out-of-Hours’ fees and fees for a range of special 
services, the cost of services provided in normal hours by GPs for 
GMS persons, including the prescribing of necessary medicines, is 
encompassed by the capitation fee. All GMS persons can avail of full 
GP services and in many cases they can benefit from specialist clinics 
provided by GPs for issues such as Women’s Health, Family Planning 
and Asthma. 
In addition to a capitation fee an ‘Out-of-Hours’ fee is payable 
for non routine consultations when a GMS cardholder is seen by 
their GP or another GP acting on his/her behalf from 5 pm in the 
evening to 9 am on the following morning (Monday to Friday) and 
all hours on Saturdays, Sundays and Bank Holidays. ‘Out-of-Hours’ 
claims increased to 961,873 in 2018 compared with 959,121 in 2017 
- expenditure on ‘Out-of-Hours’ claims during 2018 increased to 
€36,870,234 from €36,692,139 in 2017. Special fees are payable for a 
range of additional services such as excisions, suturing, vaccinations, 
catheterization, family planning etc. 1,328,715 special services 
were claimed in 2018 - with expenditure totalling €40,156,079. The 
most frequently claimed special services in 2018 were Influenza 
Vaccinations (449,032),  E.C.G. treatments (179,536) and Excisions 
(154,129). 
Annual and study leave together with locum, nursing and other 
practice support payments account for most of the  €153,656,565 
allowances paid to GPs in 2018. The amount paid in 2017 was 
€152,662,775.
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Payments to General Practitioners 2009 - 2018
Payments to General Practitioners 2009 - 2018
Year Fees Allowances Total
2009 357,799,604 141,865,756 499,665,360
2010 348,130,051 145,703,446 493,833,497
2011 342,935,677 126,426,925 469,362,602
2012 351,088,405 132,051,034 483,139,439
2013 343,404,031 136,622,499 480,026,530
2014 320,269,633 132,983,184 453,252,817
2015 348,035,815 141,659,008 489,694,823
2016 394,797,667 148,334,217 543,131,884
2017 398,912,575 152,662,775 551,575,350
2018 411,754,432 153,656,565 565,410,997
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Number of Claims by General Practitioners in each CHO
Community Healthcare 
Organisation Fee-per-Item Special Type Consultation Special Service Out-of-Hours
CHO Area 1 - 20,078 134,559 63,132
CHO Area 2 - 28,561 162,933 91,512
CHO Area 3 - 24,863 112,797 81,942
CHO Area 4 22,793 41,647 220,962 222,890
CHO Area 5 1,153 24,458 180,194 159,247
CHO Area 6 - 11,501 90,723 41,768
CHO Area 7 12,397 53,577 126,783 95,604
CHO Area 8 - 28,304 177,695 121,638
CHO Area 9 - 28,265 122,069 84,140
National 36,343 261,254 1,328,715 961,873
A majority of GPs are paid an annual capitation fee for each eligible person - the rate of payment is determined by the age/gender of the person.
A minority of GPs (3) who have continued to provide services under the Fee-per-Item of Service agreement are paid a fee for each Doctor/Patient 
contact.
A Special Type Consultation (STC) fee may be claimed when a GP provides a service to a GMS eligible person who is not on their GMS panel. 
Such GMS eligible persons may require medical services such as an Out-of-Hours, or emergency consultation, or they may be temporarily resident in 
an area not served by their GP.
General Practitioners can claim fees for special items of service provided to eligible persons under the Capitation Agreement and the Fee-per-Item 
Agreement.
Number of Claims by General Practitioners
Special Service 1,328,715
Out-of-Hours 961,873
Special Type Consultation 261,254
Fee-per-Item 36,343
National – 2018
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Number of Claims by General Practitioners 2009 - 2018
Year Fee-per-Item Special Type Consultation Special Service Out-of-Hours
2009 59,632 261,884 713,658 837,143
2010 61,408 298,354 790,908 703,623
2011 55,432 340,349 877,357 804,670
2012 57,331 367,788 884,313 861,133
2013 58,660 328,062 926,105 890,914
2014 55,047 286,222 938,890 806,522
2015 52,634 299,568 969,709 885,861
2016 46,100 307,742 1,084,881 987,711
2017 47,476 285,461 1,174,931 959,121
2018 36,343 261,254 1,328,715 961,873
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GMS: Payments to General Practitioners
2018 2017
€ €
FEES  - Capitation 277,190,633 276,492,172
 - Special Claims/Services 42,880,713 36,552,171
 - Out-of-Hours 36,870,234 36,692,139
 - Dispensing 855,561 1,031,698
 - Item of Service Contract 447,013 583,887
 - Asylum Seekers 413,209 347,206
 - Vaccinations 8,812,459 8,016,031
 - Asthma Registration 250,700 307,150
 - Asthma Capitation 918,446 1,092,915
 - Contribution for GP Height Measure and Self Zeroing Scale 2,676 6,978
 - Diabetes Capitation 8,970,202 8,258,404
 - Diabetes Registration 362,730 331,410
   
ALLOWANCES  - Secretarial/Nursing 89,418,026 87,430,736
 - Annual Leave 10,377,553 10,695,135
 - Rostering/Out-of-Hours 6,237,205 6,376,504
 - Medical Indemnity Insurance 6,685,376 7,268,948
 - Rural Practice 4,666,268 4,645,500
 - Study Leave 2,099,921 2,140,230
 - Sick Leave 1,312,582 1,508,834
 - Maternity Leave/Paternity Leave 2,007,492 1,875,795
 - Locum and Practice Expenses 4,113 5,141
   
SALARIES  - Benefits to retired DMOs and their dependants 2,238,257 2,618,366
 - Former District Medical Officers 1,307,125 1,341,918
 
SUPERANNUATION FUND  - Contribution 29,540,904 29,374,034
TOTAL €533,869,398 €524,993,302
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GMS: Number and Cost of Special Items of Service Reimbursed to GPs
Type of Service 
Number of Claims Cost of Claims
2018 2017 2018€
2017
€
A Excisions/Cryotherapy/Diathermy: Skin Lesions 154,129 155,617 3,821,363 3,858,011
AB LARC - counselling, insertion '&' monitoring from certified GP 18,376 17,741 1,286,320 1,241,870
AC Removal of a LARC Device 10,003 9,344 500,150 467,200
AD 24hr ABPM Diagnosis '&' treatment for individual patient care '&' not general/routine test 126,404 108,838 7,584,240 6,530,280
AE Cervical Screening Consultation 109,665 - 5,483,250 -
B Suturing: Cuts and Lacerations 53,984 50,630 2,697,980 2,530,162
C Hydroceles: Draining of 1,535 1,609 38,059 39,885
D Haemorrhages: Dental/Nasal 2,690 2,631 66,712 65,243
E Veins: Recognised treatment 7 11 168 264
F ECG: Tests and interpretation 179,536 166,893 4,452,140 4,138,625
G Diaphragm: Instruction in the fitting of 2 2 50 50
H Eye: Removal of adherent foreign body 12,018 12,780 298,051 316,947
J Ear/Nose/Throat: Removal of foreign body 64,091 62,678 1,589,459 1,554,409
K Nebuliser: Treatment in the case of acute asthmatic attack 94,983 92,841 3,534,157 3,453,174
L Bladder: Catheterization 9,752 9,902 584,941 594,051
M Case Conference: Convened by HSE 481 618 29,832 37,378
N Diaphragm: Advice and fitting of 1 8 42 334
O Outbreak 13 - 371 -
P IUCD: Counselling and fitting of 12 6 801 402
R Pneumococcal: Vaccination 24,266 22,003 691,581 627,085
S Influenza: Vaccination 449,032 442,975 6,735,495 6,644,694
T Pneumococcal/Influenza: Vaccination 12,576 12,012 537,624 513,509
U Hepatitis B: Vaccination 3,977 4,588 188,991 218,025
X Removal of lodged or impacted foreign bodies from the ear, nose, throat and skin  (Children aged under 6 only) 719 738 17,831 18,303
Y Suturing of cuts and lacerations (including application of tissue glue)  (Children aged under 6 only) 402 444 14,958 16,520
Z Draining of Abscess (Children aged under 6 only) 61 22 1,513 549
National 1,328,715 1,174,931 €40,156,079 €32,866,970
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PHARMACY
SECTION
36
GMS Scheme €
*Fee-Per-Item  
 -  for each of the first 1,667 items dispensed by the Community Pharmacy Contractor in a month 5.00
 -  for each of the next 833 items dispensed by the Community Pharmacy Contractor in that month 4.50
 -  for each other item dispensed by the Community Pharmacy Contractor in that month 3.50
Extemporaneous Fee 6.53
Extemporaneous dispensing and compounding of
 -  Powders 19.60
 -  Ointments and Creams 13.07
Non-Dispensing Fee - exercise of professional judgement 3.27
Phased Dispensing Fee - each part of phased dispensing 3.27
*A Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Supplies to Dispensing Doctors
Pharmacists supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price plus the relevant mark-up.
DPS/LTI/EEA Schemes and Health (Amendment) Act 1996
*The Fee-Per-Item structure shown for the GMS Scheme above, also applies to the DPS/LTI/EEA Schemes and Health 
(Amendment) Act 1996.
Reimbursement under these four schemes includes ingredient cost plus the Fee-Per-Item.          
In the case of the Drugs Payment Scheme the PCRS makes payments to Pharmacists in respect of authorised patients whose 
monthly costs of prescribed drugs and medicines are in excess of the specified monthly amount (€134 in 2018) payable to the 
Pharmacist by an individual or family.
High Tech Arrangements
Patient Care Fee: €62.03 per month.
Non Dispensing Patient Care Fee: €31.02
-  Fee payable for a maximum of 3 consecutive months where there has been no dispensing of High Tech medicines.
Opioid Substitution Treatment Scheme
Patient Care Fee: Up to a Maximum of €62.00 per month.
Scale of Fees Payable to Participating Pharmacists as at 31st December 2018
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Payments to Pharmacists: Claims Reimbursed in each CHO 
Community Healthcare Organisation *GMS **DPS LTI  EEA  Total
CHO Area 1 €92,447,955 €3,645,526 €20,317,025 €122,503 €116,533,009
CHO Area 2 €108,533,860 €5,490,053 €21,146,933 €137,359 €135,308,205
CHO Area 3 €86,627,010 €5,117,829 €19,949,098 €119,184 €111,813,121
CHO Area 4 €148,399,375 €10,306,776 €35,670,996 €194,817 €194,571,964
CHO Area 5 €124,713,384 €6,158,915 €29,755,958 €73,623 €160,701,880
CHO Area 6 €54,435,048 €9,206,350 €18,623,148 €30,203 €82,294,749
CHO Area 7 €119,867,971 €10,451,924 €34,140,619 €40,984 €164,501,498
CHO Area 8 €122,580,743 €7,432,824 €34,572,184 €63,933 €164,649,684
CHO Area 9 €108,744,523 €9,552,648 €28,518,536 €34,339 €146,850,046
National €966,349,869 €67,362,845 €242,694,497 €816,945 €1,277,224,156
*GMS  - This figure includes Stock Order costs.
               -  Also Included in the above GMS figure is an amount of €0.37m which was paid for items dispensed under Redress for Women Resident in Certain Institutions, and €13.02m 
which was paid in respect of Non GMS Reimbursable Items dispensed under Discretionary Hardship Arrangements.  
**DPS - Payments to pharmacists includes claims for reimbursement for Fertility Treatments for DPS registered patients of the National Maternity Hospital (€ 0.42m).
Additional payment of claims reimbursed to Pharmacists include: Payments to Wholesalers and Manufacturers for High Tech Drugs
and Medicines supplied to Pharmacists:High Tech Arrangements - Patient Care Fees €23,360,809
Opioid Substitution Treatment Scheme €13,445,607 High Tech Arrangements - Drugs and Medicines €781,234,364
Health (Amendment) Act 1996 €1,413,629
Dental Treatment Services Scheme €843,098
Influenza Vaccination Scheme €872,420
Pharmacy Training Grant €470,605
A GMS cardholder who is provided with a properly completed GMS 
prescription form by his or her GP can choose to have their prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of services 
under Section 59 of the Health Act, 1970.   
In 2018 there were 18.95m GMS prescription forms containing over 59.21m 
prescription items which were dispensed at a cost of €960,184,930. (This 
figure excludes the cost of GMS stock orders of €6,164,939 in 2018). This 
equates to an average cost of €16.21 per dispensed item. During 2018, 91% 
of all GMS cardholders availed of prescription items at an average cost of 
€679.40 per person. 
Payments made to Pharmacists under the GMS and DTSS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees, and VAT where 
applicable.
Under Drug Payment Scheme (DPS), Long Term Illness (LTI) and European 
Economic Area (EEA) Schemes, Pharmacists are reimbursed the ingredient 
cost of items dispensed, dispensing fees and VAT where applicable.
There were 84,109 persons who availed of High Tech Arrangements 
and patient care fees of €23.36m were paid to pharmacists under these 
arrangements. 
During 2018 the Health Service Executive processed pharmacy claims 
valued at €696.51m in respect of the three highest value categories. The 
highest value category of reimbursements was for medication acting on 
the Nervous System  - €274.80m (GMS €218.23m, DPS €22.89m and LTI 
€33.68m). The second highest reimbursement category was for medication  
to treat conditions of the Alimentary Tract and Metabolism €225.54m (GMS 
€118.28m, DPS €17.83m, LTI €89.43m). The third highest value category 
reimbursed was for medication acting on the Cardiovascular System valued 
at €196.17m (GMS €141.30m, DPS €22.29m and LTI €32.58m). 
GMS €966.35m DPS €67.36m LTI  €242.69m  EEA €0.82m
Payments to Pharmacists: Claims Reimbursed 2018
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Payments to Pharmacists: Claims Reimbursed 2009 - 2018
Year GMS DPS LTI  EEA  Total
2009 €1,260,244,615 €259,928,189 €139,759,172 €1,957,613 €1,661,889,589
2010 €1,233,261,559 €173,435,072 €126,921,779 €1,744,446 €1,535,362,856
2011 €1,207,338,461 €142,138,915 €118,098,284 €1,598,020 €1,469,173,680
2012 €1,288,815,871 €125,691,064 €117,101,875 €1,778,697 €1,533,387,507
2013 €1,222,212,846 €84,045,549 €106,510,059 €1,490,790 €1,414,259,244
2014 €1,118,945,050 €67,534,381 €139,191,408 €1,248,767 €1,326,919,606
2015 €1,054,304,114 €67,108,587 €189,483,531 €1,136,724 €1,312,032,956
2016 €1,033,290,114 €65,299,554 €207,444,771 €998,483 €1,307,032,922
2017 €989,833,465 €62,094,671 €221,903,709 €884,229 €1,274,716,074
2018 €966,349,869 €67,362,845 €242,694,497 €816,945 €1,277,224,156
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Average GMS Cost per Pharmacy Item 2009 - 2018 
Year *Total Number of Items Total Payments Average Cost per Item
2009 50,721,919 €1,260,244,615 €24.85
2010 54,424,660 €1,233,261,559 €22.66
2011 58,099,381 €1,207,338,461 €20.78
2012 62,084,126 €1,288,815,871 €20.76
2013 62,272,035 €1,222,212,846 €19.63
2014 59,524,407 €1,118,945,050 €18.80
2015 58,093,584 €1,054,304,114 €18.15
2016 58,797,149 €1,033,290,114 €17.57
2017 58,713,753 €989,833,465 €16.86
2018 59,326,912 €966,349,869 €16.29
* Total number of Items includes Stock Order Items. 
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Number of Items Claimed by Pharmacists
Number of Items claimed in each CHO 
Community Healthcare Organisation *GMS DPS LTI EEA HT Other Total
CHO Area 1 5,616,212 420,485 793,194 10,168 66,085 47,746 6,953,890
CHO Area 2 6,334,464 636,011 757,457 10,762 81,243 39,999 7,859,936
CHO Area 3 5,356,954 608,866 792,652 9,182 64,609 58,808 6,891,071
CHO Area 4 9,038,790 1,254,324 1,262,128 14,266 134,251 81,156 11,784,915
CHO Area 5 7,682,206 752,389 1,182,043 6,222 86,386 90,091 9,799,337
CHO Area 6 3,345,238 930,300 641,409 1,995 78,444 55,791 5,053,177
CHO Area 7 7,555,845 1,118,408 1,189,815 3,201 117,840 151,188 10,136,297
CHO Area 8 7,731,582 861,281 1,283,030 5,179 93,176 98,790 10,073,038
CHO Area 9 6,665,621 1,051,231 1,034,317 2,764 96,080 144,290 8,994,303
National 59,326,912 7,633,295 8,936,045 63,739 818,114 767,859 77,545,964
*GMS includes: claim items and Stock Order items.
Other: Claims: Other: Claims:
Opioid Substitution Treatment Scheme 341,822 Health (Amendment) Act 1996                       92,206
Discretionary Hardship Arrangements             132,095  Pharmacy Vaccinations                                    58,432
Dental Treatment Services Scheme                143,304
GMS: General Medical Services. DPS: Drugs Payment Scheme. LTI: Long Term Illness Scheme. EEA: European Economic Area. HT: High Tech Arrangements.
Other: Opioid Substitution Treatment Scheme, Health (Amendment) Act 1996, Dental Treatment Services Scheme, Vaccinations for GMS eligible persons (through 
Community Pharmacy) and Discretionary Hardship Arrangements.
GMS prescription forms processed for payment in the year totalled 18.95m 
- the total of prescribed items was more than 59.21m - these accounted for 
approximately 76% of all items paid for by the Primary Care Reimbursement 
Service in 2018.
Approximately 38.97% of GMS forms contained a single item - 18.83% 
contained 2 items - the average number per form was approximately 3.13 
items (2017 - 3.09). 
GMS 59.33m
DPS 7.63m
LTI 8.94m
EEA 0.06m
HT 0.82m
Other 0.77m
National – Number of Items Claimed 2018
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Number of Items Claimed by Pharmacists 2009 - 2018
Year *GMS DPS LTI EEA HT Other Total
2009 50,721,919 13,372,525 2,855,361 85,520 357,365 433,301 67,825,991
2010 54,424,660 11,070,446 2,807,757 86,445 390,838 471,231 69,251,377
2011 58,099,381 10,097,055 2,802,766 89,096 433,139 501,824 72,023,261
2012 62,084,126 9,333,838 2,944,285 96,991 522,355 743,141 75,724,736
2013 62,272,035 7,629,138 3,030,251 96,570 554,686 795,824 74,378,504
2014 59,524,407 7,007,029 4,696,579 89,210 582,744 815,567 72,715,536
2015 58,093,584 7,158,877 6,759,211 84,328 631,042 815,181 73,542,223
2016 58,797,149 7,203,742 7,593,728 76,369 681,631 823,222 75,175,841
2017 58,713,753 7,135,002 8,304,668 67,970 746,052 795,652 75,763,097
2018 59,326,912 7,633,295 8,936,045 63,739 818,114 767,859 77,545,964
*GMS includes: claim items and Stock Order items.
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																														HSE	–	Medicines	Management	Programme	(MMP)																		 	
The	Medicines	Management	Programme	(MMP)	aims	to	promote	safe,	effective	and	cost-effective	prescribing	in	Ireland.	
	
The	HSE-MMP	is	a	multidisciplinary	unit	led	by	Prof	Michael	Barry,	Clinical	Lead,	and	aims	to	provide	sustained	national	leadership	relating	to	issues	such	as	
the	quality	of	the	medicines	management	process,	access	to	medicines	and	overall	expenditure	on	medicines.	The	Preferred	Drug	initiative	is	an	ongoing	
project	supporting	prescribers	in	choosing	the	most	efficient	drug	option	in	various	therapeutic	areas.	
	
																															HSE-MMP	Preferred	Drugs	 																				
Therapeutic	Area	 HSE-MMP	Preferred	Drug	
Statin	 UNDER	REVIEW	
PPI	 UNDER	REVIEW	
ACE	inhibitor	 Ramipril	
ARB	 Candesartan	
Beta	blocker	 Bisoprolol	
Calcium	channel	blocker	 Amlodipine	
Oral	anticoagulant	 Warfarin	(DOAC:	Apixaban)	
SSRI	 Citalopram	
SNRI	 Venlafaxine	
Urinary	agent	 Tolterodine	prolonged	release	
	
 
 
	
	
	
	
	
	
	
	
Managed	access	processes	are	in	place	in	relation	to	some	medicines:		
• Versatis®	medicated	plasters		
• Entresto®	(sacubitril/valsartan)	film-coated	tablets	
• Direct	Oral	Anti-Coagulants	(DOACs)	
	
In	order	to	support	implementation	of	the	MMP	Preferred	Drugs	and	managed	access	
medicines,	the	following	resources	are	available	on	www.hse.ie/yourmedicines:	
• Evaluation	Reports	
• Prescribing	Tips	and	Tools	
	
The	MMP	has	also	published	guidance	to	support	prescribers	in	the	following	areas:	
• Inhaled	Medicines	for	Chronic	Obstructive	Pulmonary	Disease	(COPD)	
• Benzodiazepines	and	Z-drugs	(BZRA)	in	the	treatment	of	Anxiety	and	Insomnia	
• Oral	Anticoagulants	for	Stroke	Prevention	in	Non-valvular	Atrial	Fibrillation	
• Standard	Oral	Nutritional	Supplements	(ONS)	
	
For	more	information,	visit	www.hse.ie/yourmedicines		
In	2018,	the	MMP	published	the	MMP	Roadmap	for	the	prescribing	of	best-value	biological	(BVB)	medicines	in	the	Irish	healthcare	setting.	
The	MMP	will	progress	this	work	in	2019,	identifying	BVB	medicines	in	a	range	of	therapeutic	areas.	
HSE - Medicines Management Programme (MMP)
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Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 118.28 12.24
B Blood and Blood Forming Organs 76.79 7.95
C Cardiovascular System 141.30 14.62
D Dermatologicals 24.00 2.48
G Genito Urinary System and Sex Hormones 44.26 4.58
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 21.69 2.25
J Antiinfectives for Systemic Use 31.67 3.28
L Antineoplastic and Immunomodulating Agents 8.86 0.92
M Musculo-Skeletal System 52.59 5.44
N Nervous System 218.23 22.58
P Antiparasitic Products, Insecticides and Repellents 1.69 0.17
R Respiratory System 107.73 11.15
S Sensory Organs 24.29 2.51
V Various (below) 94.97 9.83
Clinical Nutritional Products 47.87 4.95
Ostomy Requisites 19.83 2.05
Urinary Requisites 11.99 1.24
Diagnostic Products 6.25 0.65
Dressings 2.51 0.26
Other Therapeutic Products 2.20 0.23
Needles/Syringes/Lancets 2.07 0.21
Allergens 0.08 0.01
Miscellaneous 2.17 0.23
Total €966.35m 100%
  
Note: The above table shows total expenditure i.e. ingredient cost, fees and VAT where applicable.
GMS: Major Therapeutic Classification of Drugs, Medicines and Appliances
National 2018
Other - 29.58%
N - 22.58%
C - 14.62%
A - 12.24%
R - 11.15%
V - 9.83%
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Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 17.83 11.35
B Blood and Blood Forming Organs 15.45 9.84
C Cardiovascular System 22.29 14.19
D Dermatologicals 4.95 3.15
G Genito Urinary System and Sex Hormones 12.99 8.27
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 3.45 2.20
J Antiinfectives for Systemic Use 4.84 3.08
L Antineoplastic and Immunomodulating Agents 2.97 1.89
M Musculo-Skeletal System 12.76 8.13
N Nervous System 22.89 14.58
P Antiparasitic Products, Insecticides and Repellents 0.35 0.22
R Respiratory System 17.03 10.85
S Sensory Organs 3.35 2.13
V Various (below) 15.90 10.12
Clinical Nutritional Products 5.53 3.52
Ostomy Requisites 5.11 3.25
Urinary Requisites 2.42 1.54
Diagnostic Products 0.69 0.44
Other Therapeutic Products 0.45 0.29
Needles/Syringes/Lancets 0.32 0.20
Dressings 0.14 0.09
Allergens 0.14 0.09
Miscellaneous 1.10 0.70
Total €157.05m 100%
  
Note: (i) The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
            (ii) The above table shows total expenditure i.e. ingredient cost, fees and VAT where applicable.
DPS: Major Therapeutic Classification of Drugs, Medicines and Appliances
National 2018
Other - 38.91%
N - 14.58%
C - 14.19%
A - 11.35%
R - 10.85%
V - 10.12%
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Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 89.43 36.85
B Blood and Blood Forming Organs 9.82 4.05
C Cardiovascular System 32.58 13.42
D Dermatologicals 0.03 0.01
G Genito Urinary System and Sex Hormones 0.75 0.31
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 1.08 0.45
J Antiinfectives for Systemic Use 1.10 0.45
L Antineoplastic and Immunomodulating Agents 0.16 0.07
M Musculo-Skeletal System 0.45 0.19
N Nervous System 33.68 13.88
P Antiparasitic Products, Insecticides and Repellents 0.01 0.00
R Respiratory System 0.63 0.26
S Sensory Organs 0.20 0.08
V Various (below) 72.77 29.98
Diagnostic Products 43.65 17.98
Needles/Syringes/Lancets 16.54 6.82
Clinical Nutritional Products 7.24 2.98
Urinary Requisites 2.91 1.20
Nutritional/Ancillary Devices 0.65 0.27
Ostomy Requisites 0.19 0.08
Other Therapeutic Products 0.05 0.02
Dressings 0.04 0.02
Miscellaneous 1.50 0.61
Total €242.69m 100%
  
Note: The above table shows total expenditure i.e. ingredient cost, fees and VAT where applicable.
LTI: Major Therapeutic Classification of Drugs, Medicines and Appliances
National 2018
A - 36.85%
V - 29.98%
C - 13.88%
N - 13.42%
Other - 5.87%
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																														HSE	–	Medicines	Management	Programme	(MMP)																		 	
Switching	
When	issuing	a	repeat	prescription	for	a	biological	medicine	containing	
adalimumab	or	etanercept,	the	clinician	should	prescribe	the	BVB	
medicine:	
• Adalimumab:	Imraldi®.	Where	the	clinician	wishes	to	prescribe	
a	citrate-free	formulation	of	adalimumab,	the	MMP	
recommends	Amgevita®.	
• Etanercept:	Benepali®	
	
	
	
Biological	medicines	containing	tumour	necrosis	factor-alpha	(TNF-α)	inhibitors	were	the	highest	expenditure	category	for	High	Tech	Arrangements	in	2018.	
The	MMP	published	the	MMP	Roadmap	for	the	prescribing	of	best-value	biological	(BVB)	medicines	in	the	Irish	healthcare	setting	in	2018.		
In	May	2019,	the	MMP	completed	an	evaluation	process	for	the	identification	of	the	BVB	medicines	for	TNF-α	inhibitors	for	High	Tech	Arrangements.	
 
                                                
The	MMP	recommends	the	following	BVB	medicines:	
• Adalimumab:	Imraldi®.	Where	the	clinician	wishes	to	prescribe	a	citrate-free	formulation	of	adalimumab,	the	MMP	recommends	Amgevita®.		
• Etanercept:	Benepali®	
Clinicians	should	give	due	consideration	to	the	prescription	of	these	agents	when	prescribing	a	TNF-α	inhibitor.	Implementation	of	the	BVB	
medicines	will	lead	to	significant	savings	for	the	health	service	in	the	order	of	millions	of	euros.	
	
	
Initiation	
When	initiating	a	patient	on	a	biological	medicine	containing	a	
TNF-α	inhibitor,	the	clinician	should	prescribe	a	BVB	medicine:	
• Adalimumab:	Imraldi®.	Where	the	clinician	wishes	to	
prescribe	a	citrate-free	formulation	of	adalimumab,	the	
MMP	recommends	Amgevita®.			
• Etanercept:	Benepali®	
	
	
For	more	information	on	best-value	biological	medicines,	visit	www.hse.ie/yourmedicines		
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The	MMP	recommends	the	following	BVB	medicines:	
• Adalimumab:	Imraldi®.	Where	the	clinician	wishes	to	prescribe	a	citrate-free	formulation	of	adalimumab,	the	MMP	recommends	Amgevita®.		
• Etanercept:	Benepali®	
Clinicians	should	give	due	consideration	to	the	prescription	of	these	agents	when	prescribing	a	TNF-α	inhibitor.	Implementation	of	the	BVB	
medicines	will	lead	to	significant	savings	for	the	health	service	in	the	order	of	millions	of	euros.	
	
	
Initiation	
When	initiating	a	patient	on	a	biological	medicine	containing	a	
TNF-α	inhibitor,	the	clinician	should	prescribe	a	BVB	medicine:	
• Adalimumab:	Imraldi®.	Where	the	clinician	wishes	to	
prescribe	a	citrate-free	formulation	of	adalimumab,	the	
MMP	recommends	Amgevita®.			
• Etanercept:	Benepali®	
	
	
For	more	information	on	best-value	biological	medicines,	visit	www.hse.ie/yourmedicines		
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49
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 1.20 0.15
B Blood and Blood Forming Organs 21.94 2.76
C Cardiovascular System 13.09 1.64
D Dermatologicals 15.46 1.94
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 31.14 3.91
J Antiinfectives for Systemic Use 18.36 2.31
L Antineoplastic and Immunomodulating Agents 577.89 72.59
M Musculo-Skeletal System 2.53 0.32
N Nervous System 10.46 1.31
R Respiratory System 101.68 12.77
V Various (below) 2.36 0.30
Other Therapeutic Products 2.36 0.30
Total €796.11m 100%
  
Note: The above table shows total expenditure i.e. ingredient cost, fees and VAT where applicable, based on claims submitted by Pharmacists.
High Tech: Major Therapeutic Classification of Drugs and Medicines
National 2018
L - 72.59%
R - 12.77%
H - 3.91%
B - 2.76%
J - 2.31%
Other - 5.66%
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GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
A  Alimentary Tract and Metabolism 8,600,386 14.50 70,992,144 11.34
A01  Stomatological Preparations 79,495 0.13 232,234 0.04
A02  Drugs for Acid Related Disorders                                   4,182,460 7.05 23,677,256 3.78
A03  Drugs for Functional Gastrointestinal Disorders 404,830 0.68 1,659,932 0.27
A04  Antiemetics and Antinauseants 41,429 0.07 3,110,411 0.50
A05  Bile and Liver Therapy 21,864 0.04 587,882 0.09
A06  Drugs for Constipation 882,618 1.49 9,265,941 1.48
A07  Antidiarrheals, Intestinal Antiinflammatory/ Antiinfective Agents 277,999 0.47 8,566,219 1.37
A09  Digestives, incl. Enzymes 25,600 0.04 1,382,533 0.22
A10  Drugs used in Diabetes 610,776 1.03 11,588,384 1.85
A11  Vitamins 833,232 1.41 4,400,713 0.70
A12  Mineral Supplements 1,239,711 2.09 6,516,028 1.04
A14  Anabolic Agents for Systemic Use 372 0.00 4,611 0.00
B  Blood and Blood Forming Organs 4,462,382 7.52 50,193,879 8.01
B01  Antithrombotic Agents 3,309,293 5.58 47,659,347 7.61
B02  Antihemorrhagics 19,086 0.03 237,403 0.04
B03  Antianemic Preparations 1,133,964 1.91 2,292,113 0.36
B05  Blood Substitutes and Perfusion Solutions 39 0.00 5,016 0.00
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GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
C  Cardiovascular System 12,426,712 20.95 73,090,503 11.67
C01  Cardiac Therapy 601,333 1.01 9,225,549 1.47
C02  Antihypertensives 202,263 0.34 1,761,422 0.28
C03  Diuretics 1,271,415 2.14 3,528,428 0.56
C04  Peripheral Vasodilators 35,279 0.06 536,748 0.09
C05  Vasoprotectives 116,396 0.20 655,393 0.10
C07  Beta Blocking Agents 2,012,239 3.39 5,483,445 0.88
C08  Calcium Channel Blockers 1,514,419 2.55 5,230,216 0.83
C09  Agents Acting on the Renin-Angiotensin System 3,081,352 5.20 21,773,202 3.48
C10  Lipid Modifying Agents 3,592,016 6.06 24,896,100 3.98
D  Dermatologicals 1,476,392 2.49 13,333,495 2.13
D01  Antifungals for Dermatological Use 384,481 0.65 2,360,997 0.38
D02  Emollients and Protectives 237,733 0.40 636,392 0.10
D03  Preparations for Treatment of Wounds and Ulcers 1,562 0.00 128,761 0.02
D04  Antipruritics, incl. Antihistamines, Anesthetics, etc. 13 0.00 475 0.00
D05  Antipsoriatics 86,042 0.15 3,849,034 0.61
D06  Antibiotics and Chemotherapeutics for Dermatological Use 123,356 0.21 982,407 0.16
D07  Corticosteroids, Dermatological Preparations 522,306 0.88 2,701,106 0.43
D10  Anti-Acne Preparations 90,341 0.15 1,350,369 0.22
D11  Other Dermatological Preparations 30,558 0.05 1,323,954 0.21
G  Genito Urinary System and Sex Hormones 2,299,164 3.88 31,319,943 5.00
G01  Gynecological Antiinfectives and Antiseptics 16,144 0.03 101,526 0.02
G02  Other Gynecologicals 29,083 0.05 1,998,762 0.32
G03  Sex Hormones and Modulators of the Genital System 971,110 1.64 6,859,573 1.09
G04  Urologicals 1,282,827 2.16 22,360,082 3.57
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GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
H  Systemic Hormonal Preparations, Excl. Sex  Hormones and Insulins 2,655,871 4.48 7,913,261 1.26
H01  Pituitary and Hypothalamic Hormones and Analogues 13,656 0.02 727,315 0.11
H02  Corticosteroids for Systemic Use 782,339 1.32 3,804,313 0.61
H03  Thyroid Therapy 1,856,305 3.13 3,300,889 0.53
H04  Pancreatic Hormones 3,571 0.01 80,744 0.01
J  Antiinfectives for Systemic Use 2,696,182 4.53 18,532,840 2.96
J01  Antibacterials for Systemic Use 2,505,271 4.22 14,543,502 2.32
J02  Antimycotics for Systemic Use 103,349 0.17 950,231 0.15
J04  Antimycobacterials 8,431 0.01 192,888 0.03
J05  Antivirals for Systemic Use 79,131 0.13 2,846,219 0.46
L  Antineoplastic and Immunomodulating Agents 356,353 0.60 6,649,583 1.06
L01  Antineoplastic Agents 30,108 0.05 1,001,949 0.16
L02  Endocrine Therapy 118,587 0.20 2,491,923 0.40
L04  Immunosuppressants 207,658 0.35 3,155,711 0.50
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GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
M  Musculo-Skeletal System 3,057,714 5.15 33,270,257 5.31
M01  Antiinflammatory and Antirheumatic Products 1,228,009 2.07 7,987,971 1.28
M02  Topical Products for Joint and Muscular Pain 783,138 1.32 5,215,432 0.83
M03  Muscle Relaxants 71,938 0.12 763,735 0.12
M04  Antigout Preparations 401,938 0.68 3,017,025 0.48
M05  Drugs for Treatment of Bone Diseases 446,390 0.75 14,852,553 2.37
M09  Other Drugs for Disorders of the Musculo-Skeletal System                                                                    126,301 0.21 1,433,541 0.23
N  Nervous System 12,956,148 21.84 139,077,904 22.21
N01  Anesthetics 27,396 0.05 1,658,689 0.27
N02  Analgesics 3,417,347 5.76 29,850,090 4.77
N03  Antiepileptics 1,448,149 2.44 36,683,399 5.86
N04  Anti-Parkinson Drugs 257,577 0.43 4,408,616 0.70
N05  Psycholeptics 3,695,304 6.23 29,207,291 4.66
N06  Psychoanaleptics 3,728,418 6.29 28,478,304 4.55
N07  Other Nervous System Drugs 381,957 0.64 8,791,515 1.40
P  Antiparasitic Products, Insecticides and Repellents 136,285 0.23 976,611 0.16
P01  Antiprotozoals 113,193 0.19 721,825 0.11
P02  Anthelmintics 7,421 0.01 35,402 0.01
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 15,671 0.03 219,384 0.04
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GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
R  Respiratory System 5,164,217 8.70 82,483,886 13.17
R01  Nasal Preparations 570,608 0.96 6,191,692 0.99
R02  Throat Preparations 4 0.00 8 0.00
R03  Drugs for Obstructive Airway Diseases 3,549,583 5.98 71,994,892 11.49
R05  Cough and Cold Preparations 301,973 0.51 1,418,351 0.23
R06  Antihistamines for Systemic Use 742,049 1.25 2,878,943 0.46
S  Sensory Organs 1,587,994 2.68 12,827,113 2.05
S01  Ophthalmologicals 1,494,367 2.52 12,525,593 2.00
S02  Otologicals 23,206 0.04 120,440 0.02
S03  Ophthalmological and Otological Preparations 70,421 0.12 181,080 0.03
V  Various 1,451,112 2.45 85,635,275 13.67
V01  Allergens 965 0.00 77,943 0.01
V03  All Other Therapeutic Products 23,532 0.04 2,052,076 0.32
V04  Diagnostic Agents 143,085 0.24 4,435,082 0.71
V06  Clinical Nutritional Products 591,213 1.00 45,317,230 7.24
V07  All Other Non -Therapeutic Products 692,317 1.17 33,752,944 5.39
        Ostomy Requisites 300,497 0.51 18,169,462 2.90
        Urinary Requisites 136,252 0.23 11,371,799 1.82
        Needles/Syringes/Lancets 90,911 0.15 1,287,952 0.21
        Dressings 40,763 0.07 1,749,033 0.28
        Miscellaneous 123,894 0.21 1,174,698 0.18
 Total 59,326,912 100.00% €626,296,694 100.00%
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DPS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
A  Alimentary Tract and Metabolism 1,058,107 13.86 12,735,234 10.98
A01  Stomatological Preparations 14,118 0.18 47,540 0.04
A02  Drugs for Acid Related Disorders                                   511,882 6.71 3,204,859 2.76
A03  Drugs for Functional Gastrointestinal Disorders 47,072 0.62 198,280 0.17
A04  Antiemetics and Antinauseants 10,156 0.13 856,384 0.74
A05  Bile and Liver Therapy 4,513 0.06 138,820 0.12
A06  Drugs for Constipation 83,497 1.09 1,049,869 0.91
A07  Antidiarrheals, Intestinal Antiinflammatory/ Antiinfective Agents 74,075 0.97 4,200,484 3.62
A08  Antiobesity Preparations, excl. Diet Products 4 0.00 246 0.00
A09  Digestives, incl. Enzymes 5,133 0.07 340,763 0.29
A10  Drugs used in Diabetes 45,236 0.59 1,111,140 0.96
A11  Vitamins 95,119 1.25 518,277 0.45
A12  Mineral Supplements 165,267 2.17 910,366 0.78
A14  Anabolic Agents for Systemic Use 1,729 0.02 23,549 0.02
A16  Other Alimentary Tract and Metabolism Products 306 0.00 134,657 0.12
B  Blood and Blood Forming Organs 621,180 8.14 12,091,299 10.43
B01  Antithrombotic Agents 495,663 6.49 11,852,659 10.22
B02  Antihemorrhagics 2,136 0.03 31,714 0.03
B03  Antianemic Preparations 123,372 1.62 206,424 0.18
B05  Blood Substitutes and Perfusion Solutions 9 0.00 502 0.00
Note: The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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DPS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
C  Cardiovascular System 1,745,494 22.87 14,295,097 12.32
C01  Cardiac Therapy 95,708 1.25 2,959,465 2.55
C02  Antihypertensives 29,568 0.39 298,977 0.26
C03  Diuretics 136,724 1.79 606,760 0.52
C04  Peripheral Vasodilators 2,445 0.03 46,272 0.04
C05  Vasoprotectives 15,384 0.20 91,948 0.08
C07  Beta Blocking Agents 281,867 3.69 868,486 0.75
C08  Calcium Channel Blockers 188,257 2.47 735,724 0.63
C09  Agents Acting on the Renin-Angiotensin System 448,565 5.88 3,837,347 3.31
C10  Lipid Modifying Agents 546,976 7.17 4,850,118 4.18
D  Dermatologicals 184,013 2.41 3,398,606 2.93
D01  Antifungals for Dermatological Use 43,797 0.57 318,234 0.27
D02  Emollients and Protectives 13,764 0.18 47,089 0.04
D03  Preparations for Treatment of Wounds and Ulcers 693 0.01 79,060 0.07
D04  Antipruritics incl. Antihistamines, Anesthetics, etc. 43 0.00 2,408 0.00
D05  Antipsoriatics 20,256 0.27 1,667,296 1.44
D06  Antibiotics and Chemotherapeutics for Dermatological Use 13,955 0.18 221,073 0.19
D07  Corticosteroids, Dermatological Preparations 68,709 0.90 400,380 0.35
D10  Anti-Acne Preparations 14,269 0.19 257,924 0.22
D11  Other Dermatological Preparations 8,527 0.11 405,142 0.35
G  Genito Urinary System and Sex Hormones 327,893 4.30 10,316,980 8.89
G01  Gynecological Antiinfectives and Antiseptics 1,119 0.02 8,524 0.01
G02  Other Gynecologicals 18,192 0.24 1,901,336 1.64
G03  Sex Hormones and Modulators of the Genital System 136,079 1.78 4,992,581 4.30
G04  Urologicals 172,503 2.26 3,414,539 2.94
Note: The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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DPS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
H  Systemic Hormonal Preparations, Excl. Sex  Hormones and Insulins 390,698 5.12 1,707,235 1.47
H01  Pituitary and Hypothalamic Hormones and Analogues 2,901 0.04 324,559 0.28
H02  Corticosteroids for Systemic Use 141,857 1.86 846,252 0.73
H03  Thyroid Therapy 245,365 3.21 522,672 0.45
H04  Pancreatic Hormones 575 0.01 13,752 0.01
J  Antiinfectives for Systemic Use 327,245 4.29 3,370,576 2.90
J01  Antibacterials for Systemic Use 290,545 3.81 2,184,798 1.88
J02  Antimycotics for Systemic Use 15,783 0.21 217,166 0.19
J04  Antimycobacterials 2,428 0.03 62,581 0.05
J05  Antivirals for Systemic Use 18,489 0.24 906,031 0.78
L  Antineoplastic and Immunomodulating Agents 94,682 1.23 2,361,687 2.04
L01  Antineoplastic Agents 7,878 0.10 521,159 0.45
L02  Endocrine Therapy 19,423 0.25 542,078 0.47
L04  Immunosuppressants 67,381 0.88 1,298,450 1.12
Note: The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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DPS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
M  Musculo-Skeletal System 392,926 5.14 9,337,087 8.05
M01  Antiinflammatory and Antirheumatic Products 161,182 2.11 1,269,772 1.09
M02  Topical Products for Joint and Muscular Pain 63,893 0.84 448,917 0.39
M03  Muscle Relaxants 6,641 0.09 68,300 0.06
M04  Antigout Preparations 68,154 0.89 581,772 0.50
M05  Drugs for Treatment of Bone Diseases 76,697 1.00 6,521,033 5.62
M09  Other Drugs for Disorders of the Musculo-Skeletal System       16,359 0.21 447,293 0.39
N  Nervous System 1,311,489 17.18 16,523,233 14.24
N01  Anesthetics 4,520 0.06 369,772 0.32
N02  Analgesics 343,463 4.50 4,336,263 3.74
N03  Antiepileptics 160,064 2.10 4,211,211 3.63
N04  Anti-Parkinson Drugs 23,822 0.31 572,675 0.49
N05  Psycholeptics 340,774 4.46 2,238,271 1.93
N06  Psychoanaleptics 414,751 5.43 4,233,100 3.65
N07  Other Nervous System Drugs 24,095 0.32 561,941 0.48
P  Antiparasitic Products, Insecticides and Repellents 24,931 0.33 241,235 0.21
P01  Antiprotozoals 24,074 0.32 221,665 0.19
P02  Anthelmintics 283 0.00 10,819 0.01
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 574 0.01 8,751 0.01
Note: The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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DPS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
R  Respiratory System 746,247 9.78 13,264,185 11.44
R01  Nasal Preparations 111,204 1.46 1,332,708 1.15
R02  Throat Preparations 506,360 6.63 11,303,161 9.74
R03  Drugs for Obstructive Airway Diseases 21,772 0.29 145,501 0.13
R05  Cough and Cold Preparations 106,911 1.40 482,815 0.42
R06  Antihistamines for Systemic Use
S  Sensory Organs 189,361 2.48 1,879,863 1.62
S01  Ophthalmologicals 175,676 2.30 1,840,385 1.59
S02  Otologicals 2,703 0.04 14,383 0.01
S03  Ophthalmological and Otological Preparations 10,982 0.14 25,096 0.02
V  Various 219,029 2.87 14,472,382 12.48
V01  Allergens 1,586 0.02 131,411 0.11
V03  All other Therapeutic Products 4,359 0.06 426,795 0.37
V04  Diagnostic Agents 12,416 0.16 508,756 0.44
V06  Clinical Nutritional Products 60,158 0.79 5,258,639 4.53
V07  All other Non-Therapeutic Products 140,510 1.84 8,146,781 7.03
        Ostomy Requisites 68,593 0.90 4,775,734 4.12
        Needles/Syringes/Lancets 20,966 0.27 162,700 0.14
        Urinary Requisites 20,077 0.26 2,304,393 1.99
        Dressings 2,558 0.03 99,212 0.09
        Miscellaneous 28,316 0.38 804,742 0.69
 Total  7,633,295 100.00% €115,994,699 100.00%
Note: The above costs are inclusive of the monthly co-payment of €134 (2018) payable to the Pharmacy by an individual or family.
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LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
A  Alimentary Tract and Metabolism 2,469,470 27.64 69,070,624 37.95
A01  Stomatological Preparations 493 0.01 2,925 0.00
A02  Drugs for Acid Related Disorders                                   22,043 0.25 272,419 0.15
A03  Drugs for Functional Gastrointestinal Disorders 2,423 0.03 165,539 0.09
A04  Antiemetics and Antinauseants 1,202 0.01 90,872 0.05
A05  Bile and Liver Therapy 683 0.01 16,835 0.01
A06  Drugs for Constipation 22,822 0.26 264,606 0.15
A07  Antidiarrheals, Intestinal Antiinflammatory/ Antiinfective Agents 820 0.01 24,058 0.01
A09  Digestives, incl. Enzymes 14,747 0.16 1,257,945 0.69
A10  Drugs Used in Diabetes 2,380,247 26.64 66,375,097 36.47
A11  Vitamins 16,322 0.18 362,380 0.20
A12  Mineral Supplements 6,708 0.07 40,358 0.02
A13  Tonics 5 0.00 52 0.00
A16  Other Alimentary Tract and Metabolism Products 955 0.01 197,538 0.11
B  Blood and Blood Forming Organs 893,784 10.00 5,942,821 3.26
B01  Antithrombotic Agents 851,122 9.53 5,861,594 3.22
B02  Antihemorrhagics 1,046 0.01 32,754 0.02
B03  Antianemic Preparations 41,506 0.46 43,917 0.02
B05  Blood Substitutes and Perfusion Solutions 110 0.00 4,556 0.00
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LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
C  Cardiovascular System 3,238,830 36.25 18,550,996 10.19
C01  Cardiac Therapy 38,689 0.44 438,521 0.24
C02  Antihypertensives 81,363 0.91 728,627 0.40
C03  Diuretics 226,102 2.53 701,755 0.39
C04  Peripheral Vasodilators 286 0.00 4,635 0.00
C05  Vasoprotectives 41 0.00 163 0.00
C07  Beta Blocking Agents 439,569 4.92 1,158,548 0.64
C08  Calcium Channel Blockers 359,342 4.02 1,258,244 0.69
C09  Agents Acting on the Renin-Angiotensin System 979,055 10.96 6,358,203 3.49
C10  Lipid Modifying Agents 1,114,383 12.47 7,902,300 4.34
D  Dermatologicals 1,423 0.01 23,816 0.01
D01  Antifungals for Dermatological Use 449 0.01 3,138 0.00
D02  Emollients and Protectives 295 0.00 1,952 0.00
D03  Preparations for Treatment of Wounds and Ulcers 4 0.00 343 0.00
 D04  Antipruritics, incl. Antihistamines, Anesthetics, etc. 2 0.00 7 0.00
D05  Antipsoriatics 71 0.00 12,654 0.01
D06  Antibiotics and Chemotherapeutics for Dermatological Use 131 0.00 761 0.00
D07  Corticosteroids, Dermatological Preparations 294 0.00 1,805 0.00
D08  Antiseptics and Disinfectants 51 0.00 391 0.00
D10  Anti-Acne Preparations 65 0.00 835 0.00
D11  Other Dermatological Preparations 61 0.00 1,930 0.00
G  Genito Urinary System and Sex Hormones 29,156 0.33 610,441 0.34
G01  Gynecological Antiinfectives and Antiseptics 78 0.00 25,998 0.02
G02  Other Gynecologicals 40 0.00 1,119 0.00
G03  Sex Hormones and Modulators of the Genital System 865 0.01 19,451 0.01
G04  Urologicals 28,173 0.32 563,873 0.31
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LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
H  Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 37,325 0.42 788,540 0.44
H01  Pituitary and Hypothalamic Hormones and Analogues 3,441 0.04 249,527 0.14
H02  Corticosteroids for Systemic Use 5,611 0.06 87,848 0.05
H03  Thyroid Therapy 9,629 0.11 36,694 0.02
H04  Pancreatic Hormones 18,644 0.21 414,471 0.23
J  Antiinfectives for Systemic Use 32,789 0.37 858,911 0.47
J01  Antibacterials for Systemic Use 31,054 0.35 786,602 0.43
J02  Antimycotics for Systemic Use 417 0.01 19,176 0.01
J04  Antimycobacterials 63 0.00 2,450 0.00
J05  Antivirals for Systemic Use 1,255 0.01 50,683 0.03
L  Antineoplastic and Immunomodulating Agents 1,883 0.02 154,353 0.09
L01  Antineoplastic Agents 788 0.01 136,891 0.08
L02  Endocrine Therapy 36 0.00 563 0.00
L04  Immunosuppressants 1,059 0.01 16,899 0.01
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LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
M  Musculo-Skeletal System 26,223 0.29 327,715 0.18
M01  Antiinflammatory and Antirheumatic Products 4,268 0.05 34,824 0.02
M02  Topical Products for Joint and Muscular Pain 1,104 0.01 8,324 0.00
M03  Muscle Relaxants 16,805 0.19 235,320 0.13
M04  Antigout Preparations 1,852 0.02 11,623 0.01
M05  Drugs for Treatment of Bone Diseases 1,934 0.02 31,940 0.02
M09  Other Drugs for Disorders of the Musculo-Skeletal System                                                                    260 0.00 5,684 0.00
N  Nervous System 847,333 9.48 29,536,946 16.23
N01  Anesthetics 352 0.00 21,164 0.01
N02  Analgesics 11,634 0.13 116,714 0.06
N03  Antiepileptics 585,095 6.55 19,323,484 10.62
N04  Anti-Parkinson Drugs 126,222 1.41 6,155,329 3.38
N05  Psycholeptics 56,561 0.63 1,840,961 1.01
N06  Psychoanaleptics 60,626 0.68 1,162,630 0.64
N07  Other Nervous System Drugs 6,843 0.08 916,664 0.51
P  Antiparasitic Products, Insecticides and Repellents 258 0.00 4,313 0.00
P01  Antiprotozoals 256 0.00 4,298 0.00
P02  Anthelmintics 1 0.00 2 0.00
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 1 0.00 13 0.00
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LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
R  Respiratory System 24,093 0.27 504,790 0.28
R01  Nasal Preparations 1,775 0.02 19,747 0.01
R02  Throat Preparations 3 0.00 8 0.00
R03  Drugs for Obstructive Airway Diseases 16,979 0.19 292,907 0.16
R05  Cough and Cold Preparations 3,888 0.04 167,908 0.09
R06  Antihistamines for Systemic Use 1,448 0.02 24,220 0.02
S  Sensory Organs 4,701 0.05 144,060 0.08
S01  Ophthalmologicals 4,594 0.05 143,647 0.08
S02  Otologicals 43 0.00 231 0.00
S03  Ophthalmological and Otological Preparations 64 0.00 182 0.00
V  Various 1,328,768 14.87 55,462,255 30.48
V03  All other Therapeutic Products 348 0.00 52,936 0.03
V04  Diagnostic Agents 766,632 8.58 32,133,289 17.66
V06  Clinical Nutritional Products 42,144 0.47 7,039,827 3.87
V07  All other Non-Therapeutic Products 519,644 5.82 16,236,203 8.92
        Needles/Syringes/Lancets/Swabs 442,218 4.95 11,512,550 6.33
        Urinary Requisites 18,934 0.21 2,824,188 1.55
        Ostomy Requisites 2,592 0.03 172,569 0.09
        Nutritional/Ancillary Devices 2,127 0.02 541,208 0.30
        Dressings 607 0.01 32,200 0.02
        Miscellaneous 53,166 0.60 1,153,488 0.63
 Total  8,936,036 100.00% €181,980,581 100.00%
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HT: Distribution of Medicines by Anatomical Therapeutic Chemical Classification 
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
A  Alimentary Tract and Metabolism 811 0.10 1,203,808 0.17
A07A  Intestinal Antiinfectives 503 0.06 169,545 0.02
A16AX  Various Alimentary Tract and Metabolism Products 308 0.04 1,034,263 0.15
B  Blood and Blood Forming Organs 41,136 5.03 18,721,734 2.62
B01  Antithrombotic Agents 415 0.05 1,376,912 0.19
B02  Antihemorrhagics 2,504 0.31 3,724,012 0.52
B03  Antianemic Preparations 38,038 4.65 12,739,911 1.79
B06  Other Hematological Agents 179 0.02 880,899 0.12
C  Cardiovascular System 13,630 1.67 13,092,794 1.84
C02  Antihypertensives 13,630 1.67 13,092,794 1.84
G  Genito Urinary System and Sex Hormones 30,235 3.70 12,582,574 1.76
G03  Sex Horomones and Modulators of the Genital System 30,235 3.70 12,582,574 1.76
Note:  Based on the data available from claims submitted by Pharmacists.
66
HT: Distribution of Medicines by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
H  Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 64,800 7.92 26,021,924 3.65
H01  Pituitary and Hypothalamic Hormones and Analogues 31,257 3.82 17,404,137 2.44
H05  Calcium Homeostasis 33,543 4.10 8,617,787 1.21
J  Antiinfectives for Systemic Use 21,211 2.58 17,606,793 2.47
J01  Antibacterials for Systemic Use 4,856 0.59 7,977,888 1.12
J02  Antimycotics for Systemic Use 2,708 0.33 4,517,746 0.63
J05  Antivirals for Systemic Use 9,932 1.21 2,353,011 0.33
J06  Immune Sera and Immunoglobulins 3,715 0.45 2,758,148 0.39
L  Antineoplastic and Immunomodulating Agents 606,699 74.16 507,470,337 71.15
L01  Antineoplastic Agents 40,762 4.98 71,576,665 10.04
L02  Endocrine Therapy 76,901 9.40 37,899,038 5.31
L03  Immunostimulants 56,095 6.86 41,522,720 5.82
L04  Immunosuppressants 432,941 52.92 356,471,914 49.98
Note:  Based on the data available from claims submitted by Pharmacists.
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HT: Distribution of Medicines by Anatomical Therapeutic Chemical Classification continued
ATC 
Class  Product Category
Prescribing 
Frequency % of Scheme Total Ingredient Cost  € % of Scheme Total
M  Musculo-Skeletal System 7,671 0.94 2,052,953 0.29
M05  Drugs for treatment of Bone Diseases 7,671 0.94 2,052,953 0.29
N  Nervous System 14,246 1.74 10,454,385 1.47
N07XX  Other Nervous System Drugs 14,246 1.74 10,454,385 1.47
R  Respiratory System 14,932 1.82 101,680,800 14.25
R05CB  Mucolytics 6,665 0.81 4,523,015 0.63
R07AX  Other Respiratory System Products 8,267 1.01 97,157,785 13.62
V  Various 2,743 0.34 2,360,778 0.33
V03AC  Iron Chelating Agents 2,743 0.34 2,360,778 0.33
 Total  818,114 100.00% €713,248,880 100.00%
Note:  Based on the data available from claims submitted by Pharmacists.
68
DENTAL
SECTION
70
Treatment Type Routine€
Oral Examination 33.00
Prophylaxis 31.00
Restoration (Amalgam) 50.06
Restoration (Composite) 6 anterior teeth only 51.88
Exodontics (Extraction under local anaesthetic) 39.50
Surgical Extraction - Maximum 2 units: 
    Fee payable for each 15 minute unit 35.00
    Maximum payable 70.00
1st Stage Endodontic Treatment (Anterior teeth only) 57.30
Denture Repairs
    1st Item of Repair 47.86
    Each Subsequent Item 15.34
    Maximum payable 78.54
Apicectomy / Amputation of Roots 168.70
Endodontics (Anterior teeth only) 137.66
Protracted Periodontal Treatment per visit (Max 4) 26.36
Miscellaneous
   (e.g. Haemorrhage and Prescriptions only) 22.65
Prosthetics
    Full Upper or Lower Denture 326.22
    Partial Upper or Lower Acrylic Denture 239.27
    Complete Upper or Lower Reline 130.59
    Complete Upper and Lower Reline 217.38
    Full Upper and Lower Denture 478.74
Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2018
71
Payments to Dentists: Claims Reimbursed in each CHO 
Community Healthcare Organisation 2018
CHO Area 1 €6,454,835
CHO Area 2 €5,870,869
CHO Area 3 €4,981,140
CHO Area 4 €9,281,021
CHO Area 5 €8,542,808
CHO Area 6 €2,850,707
CHO Area 7 €7,008,502
CHO Area 8 €7,742,156
CHO Area 9 €5,948,163
National €58,680,201
Note:   Figures include reimbursed fees in respect of Health (Amendment) Act 1996 claims.
Payments to Dentists:  Claims Reimbursed 2018
Above the Line €41.98m Below the Line €16.70m
Dentists were reimbursed a total of €58,680,201 in 2018, in respect of 
treatments provided for more than 389,791 GMS persons under the 
DTS Scheme
The following treatments were available to all GMS eligible persons.
ROUTINE:  Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’;
  ‘Above the Line’ treatments are uncomplicated 
procedures e.g. Amalgam (Filling); Extractions;
  ‘Below the Line’ treatments are advanced procedures 
e.g. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments - prior Health Service Executive approval 
for a specific course of treatment under this category is required.  Full 
denture treatment is available, with prior Health Service Executive 
approval, to all eligible GMS persons over 16 years. 
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Payments to Dentists:  Claims Reimbursed 2009 - 2018
Year Payments to Dentists 
2009 €86,834,606
2010 €75,768,061
2011 €52,260,023
2012 €63,717,122
2013 €69,749,991
2014 €69,782,332
2015 €66,505,516
2016 €64,393,261
2017 €63,369,808
2018 €58,680,201
Note:   Figures from 2017 included reimbursed fees in respect of Health (Amendment) Act 1996 claims.
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Number and Value of Dental Treatments Claimed by CHO
Community Healthcare 
Organisation *Above the Line **Below the Line
***No. of Persons 
Treated 
Value of 
Reimbursements
CHO Area 1 109,568 6,887 41,676 €6,454,835
CHO Area 2 111,083 5,716 43,026 €5,870,869
CHO Area 3 91,142 5,064 32,765 €4,981,140
CHO Area 4 168,374 9,314 61,408 €9,281,021
CHO Area 5 150,431 10,127 53,712 €8,542,808
CHO Area 6 51,537 2,687 19,633 €2,850,707
CHO Area 7 126,768 6,965 47,535 €7,008,502
CHO Area 8 138,642 7,928 52,317 €7,742,156
CHO Area 9 105,571 5,970 37,719 €5,948,163
National 1,053,116 60,658 389,791 €58,680,201
ROUTINE - Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’:
                      ‘Above the Line’ (ATL) treatments are uncomplicated procedures;
                      ‘Below the Line’ (BTL) treatments are advanced procedures.
* The most frequently used ATL service was Oral Examination, which was used by 355,161 patients followed by Amalgam Restoration.
** In the BTL category the most frequently used service was Prosthetics followed by Protracted Periodontal and Endodontics.
*** This figure is the number of unique GMS persons treated.
Note:   Figures include claims under the Health (Amendment) Act 1996.
Number of Dental Treatments Claimed 2018
Above the Line 1,053,116
Below the Line 60,658
National – Number of Treatments Claimed 2018
74
Number of Dental Treatments Claimed 2009 - 2018
Year Above the Line Below the Line No. of Persons Treated
2009 1,439,431 145,167 343,067
2010 1,304,340 104,346 382,404
2011 986,334 43,698 347,773
2012 1,138,977 59,147 394,399
2013 1,245,215 65,558 435,292
2014 1,245,135 67,248 436,433
2015 1,186,342 64,583 420,459
2016 1,151,562 63,480 416,662
2017 1,131,347 63,383 413,111
2018 1,053,116 60,658 389,791
Note:   Figures from 2017 include claims in respect of Health (Amendment) Act 1996.
OPTICAL
SECTION
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As at 31st December 2018 € As at 31st December 2018 €
Examinations Single Vision Lenses to Non-Standard Frame
Eye Examination Ophthalmic Optician 22.51 Single Vision Lens (1) (Glass) Distance 23.70 (H)
Eye Examination Ophthalmologist / Ophthalmic Medical 
Practitioner
24.78 Single Vision Lenses (2) (Glass) Distance 47.41 (H)
Single Vision Lens (1) (Glass) Reading 23.70 (H)
Medical Eye Examination by Ophthalmologist 49.58 Single Vision Lenses (2) (Glass) Reading 47.41 (H)
Eye Examination for Contact Lenses (Grant) 68.44 (H) Single Vision Lens (1) (Plastic) Distance 27.03 (H)
Eye Examination Ophthalmic (Dilation) 45.03 Single Vision Lenses (2) (Plastic) Distance 54.06 (H)
Single Vision Lens (1) (Plastic) Reading 27.03 (H)
Appliances Single Vision Lenses (2) (Plastic) Reading 54.06 (H)
Single Vision Complete Appliances
Spectacles - Distance 42.37 Additional Specification For Lenses To All Spectacle Types
Spectacles - Reading 42.37 Special grant towards additional specification for Lens (1) 82.62 (H)
Spectacles - Uncollected 29.49  - applies to all spectacle types
Contact Lenses (Pair) 42.36 Special grant towards additional specification for Lenses (2) 165.26 (H)
Contact Lenses Standard or Disposable per pair (Grant) 64.78 (H)  - applies to all spectacle types
Single Vision Spectacles - with Glass Lenses Distance 122.85 (H)
Single Vision Spectacles - with Glass Lenses Reading 122.85 (H)
Single Vision Spectacles - with Plastic Lenses Distance 132.00 (H)
Single Vision Spectacles - with Plastic Lenses Reading 132.00 (H)
Single Vision Lenses to Own Frame
Replacement Distance Lens (1) to own Frame 16.46
Replacement Distance Lenses (2) to own Frame 32.94
Replacement Reading Lens (1) to own Frame 16.46
Replacement Reading Lenses (2) to own Frame 32.94
(H)     Denotes Fees Payable in Respect of Services under the Health (Amendment) Act 1996 only.
Note:   Where applicable values are inclusive of materials and VAT.
Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme  continued
As at 31st December 2018 € As at 31st December 2018 €
Other Items - Single Vision Bifocals
Lenticular Lens (1 Surface) 11.75 Spectacles Bifocal Complete 84.19
Lenticular Lenses (2 Surfaces) 23.51 Fused Bifocal Spectacles 163.88 (H)
Lenticular Lenses (3 Surfaces) 35.27 Varifocal Spectacles - Glass or Plastic 252.73 (H)
Lenticular Lenses (4 Surfaces) 47.02
Tinted Lens (1) 7.49 Bifocal Lenses
Tinted Lenses (2) 14.98 Replacement Bifocal Lens (1) to own Frame 37.43
Tinted Lenses (3) 22.47 Replacement Bifocal Lenses (2) to own Frame 74.85
Tinted Lenses (4) 29.97 Bifocal Lens (1) to Non-Standard Frames 48.15 (H)
Prism (1) 6.36 Bifocal Lenses (2) to Non-Standard Frames 96.32 (H)
Prisms (2) 12.72 Varifocal Lens (1) (Grant) 95.61 (H)
Prisms (3) 19.09 Varifocal Lenses (2) (Grant) 191.20 (H)
Prisms (4) 25.45
Prisms (5) 31.81 Other Items - Bifocals
Prisms (6) 38.17 Sphere over 6.00 and up to 9.00 extra charge (1) Lens 4.22
Prisms (7) 44.53 Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.44
Prisms (8) 50.90 Sphere over 9.00 extra charge (1) Lens 9.37
Dioptric powers higher than 8.00  (1) Lens 6.25 Sphere over 9.00 extra charge (2) Lenses 18.75
Dioptric powers higher than 8.00  (2) Lenses 12.50 Tinted Lens (1) 8.27
Dioptric powers higher than 8.00  (3) Lenses 18.75 Tinted Lenses (2) 16.55
Dioptric powers higher than 8.00  (4) Lenses 24.99 Prism (1) 8.84
Anti-Reflective Coating on Plastic Lens (1) 18.33 (H) Prisms (2) 17.67
Anti-Reflective Coating on Plastic Lenses (2) 36.66 (H)
Dioptric powers higher than 6.00 (Plastic) (1) Lens 15.62 Repairs
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 31.24 Replacement Frame to own Lenses 12.16
Dioptric powers higher than 6.00 (Plastic) (3) Lenses 46.86 Replacement front to own Lenses 5.83
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 62.48 Replacement Side (1) to own Frame 2.45
Plastic Lens (1) for children as prescribed 4.73 Replacement Sides (2) to own Frame 4.90
Plastic Lenses (2) for children as prescribed 9.45 Complete new Frames 90.60 (H)
Plastic Lens (1) Adult 4.58 (H)
Plastic Lenses (2) Adult 9.16 (H)
(H)      Denotes Fees Payable in Respect of Services under the Health (Amendment) Act 1996 only.
Note:   Where applicable values are inclusive of materials and VAT.
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Payments to Optometrists/Ophthalmologists: Claims Reimbursed 2018
Payments to Optometrists/Ophthalmologists: Claims Reimbursed in each CHO
Community Healthcare Organisation 2018
CHO Area 1 €2,846,375
CHO Area 2 €2,943,272
CHO Area 3 €2,366,591
CHO Area 4 €3,720,985
CHO Area 5 €3,927,729
CHO Area 6 €1,673,728
CHO Area 7 €3,505,114
CHO Area 8 €3,598,170
CHO Area 9 €2,405,087
National €26,987,051
Additional payments to Optometrists and Ophthalmologists during 2018 included: 
Optical services for Children                   €2,263,594
Optical services for Teenagers                   €461,463
Health (Amendment) Act 1996                 €119,932
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult 
medical card holders, which include free eye examinations and 
necessary spectacles/appliances.  
Payments in respect of spectacles provided under the Children’s 
Scheme are also made by the Primary Care Reimbursement Service 
on behalf of the majority of Health Service Executive Areas. 
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible 
medical card holders on behalf of certain Health Service Executive 
Areas. 
In the 12-month period to the end of December 2018, claims were 
received on behalf of 287,305 GMS persons for 691,965 treatments 
costing €26,987,051.
Eye examinations by Optometrists/Ophthalmologists totalled 
299,309; complete spectacles (distance, reading and bi-focals) and 
other appliances provided under the Scheme totalled 392,656.
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Payments to Optometrists/Ophthalmologists: Claims Reimbursed 2009 - 2018
Year *Payments to Optometrists/Ophthalmologists
2009 €22,184,541
2010 €25,178,002
2011 €26,129,947
2012 €28,384,091
2013 €29,428,465
2014 €29,380,087
2015 €29,253,405
2016 €29,809,064
2017 €29,892,456
2018 €26,987,051
Note:   * Figures exclude payments for HAA, Teenagers and Children.
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Number of Treatments by Optometrists/Ophthalmologists
Number of Treatments by Optometrists/Ophthalmologists in each CHO
Community Healthcare 
Organisation Eye Examinations Appliances *No. of Persons Treated
**Value of 
Reimbursements
CHO Area 1 31,808 42,780 32,280 €2,846,375
CHO Area 2 31,370 44,408 31,706 €2,943,272
CHO Area 3 26,119 36,582 25,709 €2,366,591
CHO Area 4 43,542 52,732 39,002 €3,720,985
CHO Area 5 42,690 62,337 43,641 €3,927,729
CHO Area 6 19,709 20,183 16,601 €1,673,728
CHO Area 7 38,636 48,620 35,561 €3,505,114
CHO Area 8 39,323 51,383 37,892 €3,598,170
CHO Area 9 26,112 33,631 24,913 €2,405,087
National 299,309 392,656 287,305 €26,987,051
Note:   * This figure is the number of unique GMS persons treated.
              ** Figures exclude payments for HAA, Teenagers and Children.
National Number of Treatments 2018
Appliances 392,656
Eye Exams 299,309
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Number of Treatments by Optometrists/Ophthalmologists 2009 - 2018
Year Eye Examinations Appliances *No. of Persons Treated **Value of Reimbursements
2009 242,336 322,270 238,844 €22,184,541
2010 273,124 364,726 269,076 €25,178,002
2011 289,924 385,917 279,505 €26,129,947
2012 313,960 416,669 307,522 €28,384,091
2013 326,268 432,007 317,218 €29,428,465
2014 324,668 431,637 317,731 €29,380,087
2015 323,594 432,442 315,040 €29,253,405
2016 328,896 438,384 318,021 €29,809,064
2017 327,968 442,773 318,570 €29,892,456
2018 229,309 392,656 287,305 €26,987,051
Note:   * This figure is the number of unique GMS persons treated.
              ** Figures exclude payments for HAA, Teenagers and Children.
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